UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 14A
(Rule14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a)
of the
Securities Exchange Act of 1934
(Amendment No. ___ )
Filed by the Registrant ☒ [X]
Filed by a Party other than the Registrant ☐[ ]
Check the appropriate box:
Preliminary Proxy Statement |
Confidential, for Use of the Commission Only (as permitted by Rule14a-6(e)(2)) |
Definitive Proxy Statement |
Definitive Additional Materials |
Soliciting Material Pursuant toSection 14a-12 |
Meridian Bioscience, Inc.
(Name of Registrant as Specified in Its Charter)
(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)
Payment of Filing Fee (Check the appropriate box):
No fee required. |
Fee computed on table below per Exchange Act Rules14a-6(i)(1) and0-11. |
(1) | Title of each class of securities to which transaction applies: |
(2) | Aggregate number of securities to which transaction applies: |
(3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): |
(4) | Proposed maximum aggregate value of transaction: |
(5) | Total Fee Paid: |
Fee paid previously with preliminary materials. |
Check box if any part of the fee is offset as provided by Exchange Act Rule0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
(1) | Amount Previously Paid: |
(2) | Form, Schedule or Registration Statement No.: |
(3) | Filing Party: |
(4) | Date Filed: |
3471 River Hills Drive
Cincinnati, Ohio 45244
www.meridianbioscience.com
Notice of Annual Meeting of Shareholders
and Proxy Statement
Dear Shareholders:
OurOn behalf of the Board of Directors, I invite you to attend our Annual Meeting of Shareholders will be heldon January 26, 2022 at 2:00 p.m. on January 24, 2019 atEastern Time, which will be held virtually. We believe that hosting a virtual meeting provides expanded access, improved communication and cost savings to our shareholders and the Meridian Innovation Center, 7007 Valley Avenue, Cincinnati, Ohio 45244. We hopeCompany, and also aligns with our interests in the health and safety of our shareholders and employees during this time when COVID-19 remains a concern. You will be able to attend the Annual Meeting online, vote your shares electronically and submit your questions during the Annual Meeting by visiting www.virtualshareholdermeeting.com/VIVO2022. There will not be a physical meeting location and you will attend.
Atnot be able to attend the meeting, you will hear a report on our operations and have a chance to meet your Directors and Executive Officers.Annual Meeting in person.
This booklet includes the formal notice of the meeting and the proxy statement. The proxy statement tells you more about the agenda and procedures for the meeting. It also describes how the Board operates and gives personal information about our Directordirector candidates.
Pursuant to the Securities and Exchange Commission rulerules allowing companies to furnish proxy materials to their shareholders over the internet, a Notice of Internet Availability of Proxy Materials (the “Notice”) was sent to shareholders on or about December 13, 2018.15, 2021. The Notice contains information on how to access copies of the proxy materials and vote your shares.
Whether or not you plan tovirtually attend the meeting, please cast your proxy vote promptly, either online, over the phone or by returning your signed and dated proxy card in the enclosed envelope.
Sincerely yours,
/s/ David C. Phillips
David C. Phillips
Chairman of the Board
December 13, 201815, 2021
IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS
FOR THE ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 26, 2022
Date:
January 24, 2019
Time:
2:00 p.m., Eastern Standard Time
Place:
Meridian Bioscience, Inc.
Meridian Innovation Center
7007 Valley Avenue
Cincinnati, Ohio 45244
Purpose:
Elect as Directors the eight nominees named in the accompanying proxy materials
Conduct an advisory vote on our executive compensation(“Say-on-Pay”)
Ratify appointment of Grant Thornton LLP as Meridian’s independent registered public accountants for fiscal year 2019
Only shareholders of record on November 30, 2018 may vote at the meeting. The approximate mailing date of thisThis proxy statement and accompanying Proxy Card is December 13, 2018.our 2021 Annual Report to Shareholders are available at www.proxyvote.com
Your vote is important. Please cast your proxy vote promptly, either online, over the phone or by returning your signed and dated proxy card in the enclosed envelope.
By order of the Board of Directors,
/s/ Melissa A. Lueke
Melissa A. Lueke
Secretary
December 13, 2018
Date: | January 26, 2022 | |||
Time: | 2:00 p.m., Eastern Time | |||
Place: | Online at www.virtualshareholdermeeting.com/VIVO2022 | |||
Purpose: | ||||
● | Elect as directors the eight nominees named in the accompanying proxy materials; | |||
● | Ratify the appointment of Ernst & Young LLP as Meridian’s independent registered public accounting firm for fiscal year 2022; and | |||
● | Conduct an advisory vote on our executive compensation (“Say-on-Pay”). | |||
Only shareholders of record on December 2, 2021 may vote at the meeting. The approximate mailing date of this proxy statement and accompanying proxy card is December 15, 2021. Your vote is important. Whether or not you plan to virtually attend the 2022 annual meeting, please cast your proxy vote promptly, either online, over the phone or by returning your signed and dated proxy card in the enclosed envelope. By Order of the Board of Directors, /s/ Bryan T. Baldasare Bryan T. Baldasare Executive Vice President, Chief Financial Officer and Secretary December 15, 2021 |
Meridian makes available, free of charge on its website, all of its filings that are made electronically with the Securities and Exchange Commission (“SEC”), including Forms10-K,10-Q10-K, 10-Q and8-K. These filings are also available on the SEC’s website (www.sec.gov)(www.sec.gov). To access these filings, go to our website (www.meridianbioscience.com)(www.meridianbioscience.com). Copies of Meridian’s Annual Report on Form10-K for the fiscal year ended September 30, 2018,2021, including consolidated financial statements and schedules thereto, filed with the SEC, are also available without charge to shareholders upon written request addressed to:
Melissa A. LuekeCharles Wood, Jr.
Executive Vice President, Chief Financial Officer and SecretaryInvestor Relations
Meridian Bioscience, Inc.
3471 River Hills Drive
Cincinnati, Ohio 45244
MERIDIAN BIOSCIENCE, INC.
3471 River Hills Drive
Cincinnati, Ohio 45244
Telephone (513)271-3700
P R O X Y S T A T E M E N T
Annual Meeting of Shareholders
January 26, 2022
January 24, 2019
Who may vote
Shareholders of Meridian, as recorded in our stock register on November 30, 2018,December 2, 2021, may vote at the meeting. As of that date, Meridian had 42,463,10243,512,743 shares of Common Stockcommon stock outstanding.
Location of Annual Meeting
The Annual Meeting will again be conducted as a virtual meeting of shareholders by means of a live webcast. We believe that hosting a virtual meeting provides greater shareholder attendance and participation from any location, improved communication and cost savings to our shareholders and Company, and also aligns with our interests in the health and safety of our shareholders and employees during this time when COVID-19 remains a concern. By visiting www.virtualshareholdermeeting.com/VIVO2022, you will be able to attend the Annual Meeting, vote your shares, and submit your questions during the meeting via the internet. There will not be a physical meeting location and you will not be able to attend in person. We invite you to attend the Annual Meeting and request that you vote on the proposals described in this proxy statement. However, you do not need to attend the meeting to vote your shares. Instead, you may vote by internet, by telephone, or, if you requested and received paper copies of the proxy materials by mail, you may also vote by completing and mailing your proxy card.
How to vote
You may vote in personelectronically at the meeting, by telephone, online, or by completing and returning a proxy card. We recommend you vote by proxy even if you plan to attend the virtual meeting. You can always change your vote, by voting electronically, at the meeting.
How proxies work
Meridian’s Board of Directors is asking for your proxy. Giving us your proxy means you authorize us to vote your shares at the meeting in the manner you direct. You may vote for all, some or none of our Directordirector candidates. You may also vote for or against the other proposals or abstain from voting.
If you complete your proxy online, over the phone or sign and return the enclosed proxy card but do not specify how to vote, we will vote your shares in favor of: (i) the election of our Directordirector candidates; (ii) our executive compensation; and (iii)the ratification of the appointment of Grant ThorntonErnst & Young LLP as Meridian’s independent registered public accountantsaccounting firm for fiscal year 2019.2022; and (iii) our executive compensation. If any other matters come before the meeting or any continuation, postponement or adjournment, thereof, each proxy will be voted in the discretion of the individuals named as proxies on the card.
You may receive more than one proxy or voting card depending on how you hold your shares. Shares registered in your name are covered by one card. If you hold shares through someone else, such as a stockbroker, bank or nominee, you may get material from them asking how you want to vote.
Stockbrokers, banks and nominees holding shares for beneficial owners must vote those shares as instructed by you. If the stockbroker, bank or nominee has not received instructions from you, the beneficial owner, the stockbroker, bank or nominee generally has discretionary voting power only with respect to the ratification of appointment of the independent registered public accountants.accounting firm. However, a stockbroker, bank or nominee does not have discretion to vote for or against the election of Directorsdirectors and certain other matters subject to a vote if they have not received voting instructions from you. In order to avoid a brokernon-vote of your shares on the election of Directorsdirectors and the other matters subject to a vote, you must send voting instructions to your stockbroker, bank or nominee.
Solicitation of proxies
Solicitation of proxies is being made by management at the direction of Meridian’s Board of Directors, without additional compensation, through the mail, in person or by telephone. The cost of preparing and mailing the Notice and the proxy statement and any accompanying material will be borne by Meridian. In addition, Meridian will request brokers and other custodians, nominees and fiduciaries to forward proxy soliciting material to the beneficial owners of shares held of record, and Meridian will reimburse them for their expenses in so doing.
Revoking a proxy
You may revoke your proxy before it is voted by submitting a new proxy with a later date, by voting in personelectronically at the meeting or by notifying Meridian’s SecretaryVice President, Investor Relations in writing at the address under “Questions” on page 3134 of this proxy statement.
Quorum
In order to carry on the business of the meeting, we must have a quorum. This means at least a majority of the outstanding shares eligible to vote must be represented at the meeting, either by proxy or in person.
Votes needed
The eight Directordirector candidates receiving the most votes will be elected to fill the seats on the Board.Board (Proposal No. 1). The ratification of appointment of accounting firm (Proposal No. 2), and the approval on an advisory basis of our executive compensation (Proposal No. 2) and the ratification of appointment of accountants (Proposal No. 3) require the favorable vote of a majority of the votes cast. Only votes for or against these proposals count, with abstentions not being counted either for or against these proposals.
Abstentions and brokernon-votes count for quorum purposes but as indicated above, will not count for voting purposes. Brokernon-votes occur when a broker returns a proxy card but does not have authority to vote on a particular proposal.
Other matters
Any other matters considered at the meeting, including any continuation, postponement or adjournment, will require the affirmative vote of a majority of the votes cast.
The Virtual Meeting
We will be hosting the Annual Meeting only by means of a live webcast. There will not be a physical meeting location and you will not be able to attend the meeting in person. Please be assured that you will be afforded the same rights and opportunities to participate in the virtual meeting and ask questions as you would at an in-person meeting. By going to www.virtualshareholdermeeting.com/VIVO2022, you will be able to listen to the Annual Meeting, submit questions and vote. If you wish to listen to the Annual Meeting, but do not wish to submit questions or vote during the Annual Meeting, you may go to www.virtualshareholdermeeting.com/VIVO2022 and log in as a guest. We will post a recording of the meeting, including appropriate questions received during the meeting and the Company’s answers, on the investor page of www.meridianbioscience.com as soon as practicable after the meeting.
The Annual Meeting will start at 2:00 p.m. (Eastern Time) on January 26, 2022. We encourage you to access the meeting website prior to the start time to allow time for check-in. If you encounter any technical or logistical issues or difficulties accessing the virtual meeting during the check-in or meeting time, please call the technical support number that will be posted on the Virtual Shareholder Meeting login page.
You do not need to register to attend the Annual Meeting webcast. Follow the instructions on your Notice of Internet Availability or proxy card (if you requested and received a printed copy of the proxy materials) to access the Annual Meeting.
If you wish to submit a question the day of the Annual Meeting, you may log in to the virtual meeting platform at www.virtualshareholdermeeting.com/VIVO2022, type your question into the “Ask a Question” field, and click “Submit.” Questions pertinent to meeting matters will be answered during the Annual Meeting, subject to time constraints. Questions regarding personal matters, including those related to employment, are not pertinent to annual meeting matters and, therefore, will not be answered. We will post on the Virtual Meeting page additional guidelines for shareholder questions, rules around what types of questions are allowed, and any other procedures for how questions and comments will be recognized.
The Nominating and Corporate Governance Committee of the Board of Directors has nominated forre-election the following current Directors:directors: James M. Anderson, Anthony P. Bihl III, Dwight E. Ellingwood, Jack Kenny, John C. McIlwraith, David C. Phillips, John M. Rice, Jr., Catherine A. Sazdanoff, and Felicia Williams.
Proxies solicited by the Board will be voted for the election of these nominees. All Directorsdirectors elected at the Annual Shareholders’ Meeting will be elected to hold office until the next annual meeting. In voting to elect Directors,directors, shareholders are entitled to cumulate their votes and to give one candidate a number of votes equal to the number of Directorsdirectors to be elected multiplied by the number of shares held by the shareholder, or to distribute their votes on the same principle among as many candidates as the shareholder sees fit. In order to invoke cumulative voting, notice of cumulative voting must be given in writing by a shareholder to the CEO,Chief Executive Officer, a Vice President or the Assistant Secretary of Meridian not less than 48 hours prior to the Annual Shareholders’ Meeting. The proxies solicited include discretionary authority to cumulate votes.
All Meridian Directorsdirectors are elected forone-year terms. Personal information on each of our nominees is given below.
If a Directordirector nominee becomes unavailable before the election, your proxy card authorizes us to vote for a replacement nominee if the Board names one.
The Board recommends that shareholdersyou voteFOR each of the following candidates:
James M. Anderson Director since 2009 Age: | James M. Anderson serves as Chairman of the Compensation Committee. He currently serves as Senior Strategic and External Affairs Advisor with Taft Stettinius & Hollister LLP and President Emeritus of Cincinnati Children’s Hospital Medical Center (“CCHMC”), after having served as advisor to the President of CCHMC from January 2010 through June 30, 2017 and as President and Chief Executive Officer of CCHMC from 1996 through 2009. Mr. Anderson serves on the board of managers of CincyTech, a firm that provides advice and capital to entrepreneurs, helps research institutions commercialize technology through startups, and catalyzes investment from individuals and institutions to regional companies. In addition, he serves on the board of directors of Cintrifuse, an organization |
whose purpose is to stimulate and support the Greater Cincinnati regional start-up community and the connections between start-ups and larger, more established enterprises. From 2006 to 2014, he served as a director of Ameritas Mutual Holding Company and has also served as Chairman of the Board of the Cincinnati Branch of the Federal Reserve Bank of Cleveland, retiring in 2012. Prior to joining the staff of CCHMC, Mr. Anderson was a partner in the general corporate law department at Taft, Stettinius & Hollister for 24 years | ||
Anthony P. Bihl III Director since 2020 Age: 65 | Anthony P. Bihl served as Chief Executive Officer and a member of the board of managers of Bioventus, LLC, a company that develops, manufactures and sells products that promote active orthopedic healing, from December 2013 to April 2020. From June 2011 through June 2012, he was Group President of American Medical Systems, or AMS, a subsidiary of Endo Pharmaceuticals. Mr. Bihl was President, Chief Executive Officer and a director of AMS from April 2008 until Endo acquired AMS in June 2011. He served as Chief Executive Officer of the Diagnostics Division of Siemens Medical Solutions from January to November 2007, and as President of the Diagnostics Division of Bayer HealthCare from 2004 through 2006. Prior to that, Mr. Bihl served in a number of operations and finance roles at Bayer HealthCare and for over 20 years at E.I. DuPont. Mr. Bihl is a director and Chairman of the Board of Spectral Medical, Inc. (TSX: EDTXF), a Canadian company that develops products for the diagnosis and treatment of severe sepsis and septic shock, and Sonendo, Inc. (NYSE:SONX), a leading dental technology company that began trading on the New York Stock Exchange on October 29, 2021. In addition, Mr. Bihl currently serves on the boards of directors of Flowonix Medical Inc., a privately-held company that develops and markets targeted drug delivery platforms (since July 2020). Mr. Bihl previously served as a member of the board of directors of Nuvectra Corporation (OTC: NVTRQ) from March 2016 to May 2020 and prior to March 2016, served on the board of directors of Integer Holdings Corporation (NYSE: ITGR) before it spun off Nuvectra. The Board believes that Mr. Bihl is well qualified to serve on Meridian’s Board considering his more than 30 years of experience in the medical device industry in a variety of operations, finance and general management roles. | |
Dwight E. Ellingwood Director since 2014 Age: | Dwight E. Ellingwood |
believes that the Company benefits greatly from Mr. Ellingwood’s extensive experience in management, strategy and business development in the health care industry. | ||
Jack Kenny Director since 2017 Age: | Jack Kenny serves as Meridian’s Chief Executive Officer, having joined the Company on October 9, 2017. Before joining Meridian, Mr. Kenny served as Senior Vice President and General Manager, North America, with Siemens Healthcare, a position he held from October 2014 to May 2017. From June 2012 through October 2014, Mr. Kenny served as Vice President and General Manager, U.S. Region, for Becton Dickinson, Diagnostic Systems. Prior to June 2012, Mr. Kenny held executive roles at Danaher Corporation and Quest Diagnostics. Mr. Kenny’s experience as a key executive leader within large public companies in the health care and medical device industry, as well as his ongoing insights into Meridian’s business and operations, makes him a valuable member of the Board. |
John C. McIlwraith Director since 2015 Age: | John C. McIlwraithco-founded Allos Ventures, a venture capital firm, in March 2010 and has served as a Managing Director there since that time. Prior to founding Allos Ventures, Mr. McIlwraith was a Managing Director of Blue Chip Venture Company, a Cincinnati-based venture capital firm, which he joined in 1997. He has served on the board of directors of more than 20 health care or information technology | ||
| |||
John M. Rice, Jr. Director since 2017 Age: | John M. Rice is a Managing Director leading the Life Sciences practice at CincyTech, a firm that provides advice and capital to entrepreneurs, helps research institutions commercialize technology through start-ups, and catalyzes investment from individuals and institutions to regional companies, having previously served as Director of Life Sciences since 2014. Dr. Rice is also the founder |
Catherine A. Sazdanoff Director since 2015 Age: | Catherine A. Sazdanoff | |
Felicia Williams Director since 2018 Age: | Felicia Williams serves as Chairwoman of the Audit Committee. Ms. Williams is currently serving as the Macy’s Inc. Fellow for CEO Action for Racial Equality, a fellowship that provides the 1,500+ CEO signatories of CEO Action for Diversity & Inclusion with an opportunity to advance racial equity through public policy to address systemic racism and social injustice and improve societal well-being. Prior to becoming a Fellow, Ms. Williams served as Macy’s Interim Chief Financial Officer and Enterprise Risk Officer from June 2020 to November 2020. Since joining Macy’s in June 2004, Ms. Williams has served as Executive Vice President, Controller and Enterprise Risk Since March 2021, Ms. Williams has served as a director and member of the audit committee of Realogy Holdings Corp. (NYSE:RLGY), a leading provider of U.S. residential real estate services. Ms. Williams brings broad and wide-ranging accounting, finance, treasury and enterprise risk management experience, including analyzing financial statements, complex accounting issues and internal controls over financial reporting, which |
ADVISORY VOTE ON COMPENSATIONRATIFICATION OF NAMED EXECUTIVE OFFICERS(“SAY-ON-PAY” PROPOSAL)APPOINTMENT OF ERNST & YOUNG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
(Item 2 on the Proxy Card)
The Dodd-Frank Wall Street ReformOur Audit Committee has appointed Ernst & Young LLP (“Ernst & Young” or “the Firm”) as our independent registered public accounting firm for the fiscal year ending September 30, 2022. In evaluating the appropriateness of engaging Ernst & Young as the Company’s independent registered public accounting firm, the Audit Committee considered a number of factors including, but not limited to: (i) Ernst & Young’s relevant technical expertise and Consumer Protection Act (“Dodd Frank”), enacted in July 2010, requires that we provide our shareholdersits significant institutional knowledge of the Company’s operations and industry; (ii) the quality and candor of the Firm’s communications with the opportunity to vote to approve,Audit Committee and management; (iii) the Firm’s independence, including the consideration of any non-audit services provided and their impact on anon-binding, advisory basis,independence; (iv) the compensation of our named executives officers as disclosed in this proxy statement in accordance with the compensation disclosure rulesquality and efficiency of the Securities and Exchange Commission (“SEC”). Dodd Frank also provides that shareholders periodically be given the opportunity to vote, on anon-binding, advisory basis, for their preference as to how frequently we should seek future advisory votesservices provided, including input from management on the compensationFirm’s performance, objectivity and professional skepticism; (v) external data on audit quality and performance, including recent Public Company Accounting Oversight Board (“PCAOB”) reports on the Firm and its peer firms; (vi) the appropriateness of our named executive officers. This opportunity was providedthe Firm’s fees; and (vii) the Firm’s tenure as independent auditors, including the benefits of a longer tenure, and the controls and processes in place that help ensure the Firm’s continued independence. Ernst & Young has served as the Company’s independent registered public accounting firm since December 2020. Our Board has directed that this appointment be submitted to our shareholders at our 2018 annual meeting, where over 80%for ratification. Although ratification of our voting shareholders voted to hold the“say-on-pay” advisory vote annually, in accordance with the recommendationappointment of our Board of Directors. As a result, we are again holding asay-on-pay advisory vote at our 2019 annual meeting, with the nextsay-on-pay advisory vote to be held at our 2020 annual meeting.
As described below under the heading “Compensation Discussion and Analysis” beginning on page 15 of this proxy statement, we seek to closely align the interests of our named executive officers with the interests of our shareholders. We structure our programs to discourage excessive risk-taking through a balanced use of compensation vehicles and metrics with an overall goal of delivering sustained long-term shareholder value while aligning our executives’ interests with those of our shareholders. Further, our programs require that a substantial portion of each named executive officer’s compensation be contingent on delivering performance results that benefit our shareholders. Our compensation programs are designed to reward our named executive officers for the
achievement of short-term and long-term strategic and operational goals and the achievement of increased total shareholder return.
The vote on this matterErnst & Young is not intended to address any specific element of compensation; rather, the vote relates to the compensation of our named executive officers, as described in this proxy statement in accordance with the compensation disclosure rules of the SEC. The vote is advisory, which means that the vote is not binding on the Company, our Board of Directors or the Compensation Committee. The Board and the Compensation Committee will review and consider the voting results when making future decisions regarding our executive compensation program.
Accordingly, we ask our shareholders to approve, on an advisory basis, the compensation of the named executive officers, as disclosed in this proxy statement pursuant to the compensation disclosure rules of the SEC, including the Compensation Discussion and Analysis, the Summary Compensation Table and the other related tables and disclosure.
The Board recommends that shareholders voteFOR the approval of the compensation of our named executive officers as disclosed in this proxy statement.
RATIFICATION OF APPOINTMENT OF GRANT THORNTON LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS
(Item 3 on the Proxy Card)
Although not required, we are seekingvalue the opinions of our shareholders and believe that shareholder ratification of the Audit Committee’s selection of Grant Thornton LLPour appointment is a good corporate governance practice.
Ernst & Young also served as Meridian’sour independent registered public accountantsaccounting firm for the 2019 fiscal year. The affirmative voteyear ended September 30, 2021. Neither the Firm nor any of its members has any direct or indirect financial interest in or any connection with us in any capacity other than as our auditors, providing audit and non-audit related services. A representative of Ernst & Young is expected to virtually attend the Annual Meeting and to have an opportunity to make a majoritystatement and be available to respond to appropriate questions from shareholders. In the event that the appointment of shares voting at the meeting is required for ratification. If ratificationErnst & Young is not obtained,ratified by the shareholders, the Audit Committee intends to continue the engagement of Ernst & Young at least through the fiscal year ending September 30, 2022. Even if the appointment of Ernst & Young is ratified, the Audit Committee retains the discretion to appoint a different independent auditor at any time if it determines that such a change is in the interests of the Company.
Recent Change in Accounting Firm
Following a request for proposal (“RFP”) process, effective December 22, 2020 (the “Effective Date”), the Audit Committee of the Board of Directors of Meridian selected Ernst & Young as the Company’s independent registered public accounting firm for the Company’s fiscal year ended September 30, 2021. The Audit Committee dismissed Grant Thornton LLP at least(“Grant Thornton”), the Company’s then current independent registered public accounting firm, effective as of the Effective Date.
Grant Thornton’s reports on the Company’s Consolidated Financial Statements as of and for the fiscal years ended September 30, 2020 and 2019 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles. During the fiscal years ended September 30, 2020 and 2019, and the subsequent interim period through fiscal 2019. Representativesthe Effective Date, there were: (i) no disagreements within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions between the Company and Grant Thornton on any matters of accounting principles or practices, consolidated financial statement disclosure, or auditing scope or procedure which, if not resolved to Grant Thornton’s satisfaction, would have caused Grant Thornton to make reference thereto in their reports; and (ii) no “reportable events” within the meaning of Item 304(a)(1)(v) of Regulation S-K.
The Company requested that Grant Thornton furnish a letter addressed to the SEC stating whether or not it agrees with the above statements, and, if not, stating the respects in which it does not agree. A copy of Grant Thornton LLP are expectedThornton’s letter agreeing with the above statements, dated December 28, 2020, was filed as Exhibit 16.1 to Meridian’s Form 8-K filed on or about December 30, 2020.
During the fiscal years ended September 30, 2020 and 2019 and the subsequent interim period through the Effective Date, neither the Company nor anyone on its behalf consulted with Ernst & Young regarding: (i) the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be present atrendered on the meetingCompany’s Consolidated Financial Statements, and will be availableneither a written report nor oral advice was provided to makethe Company that Ernst & Young concluded was an important factor considered by the Company in reaching a statement, if they so desire,decision as to any accounting, auditing, or financial reporting issue; (ii) any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K and to respond to appropriate questions asked by shareholders.the related instructions; or (iii) any “reportable event” within the meaning of Item 304(a)(1)(v) of Regulation S-K.
Principal Accounting Firm Fees
Aggregate fees billed to Meridian by Ernst & Young and Grant Thornton LLP for fiscal years 20182021 and 20172020, as applicable, are listed below:
Ernst & Young | ||||||||||||||||
2018 | 2017 | 2021 | 2020 | |||||||||||||
Audit Fees | $ | 717,043 | $ | 631,374 | $ | 702,500 | $ | - | ||||||||
Audit-Related Fees | 44,213 | 39,450 | - | - | ||||||||||||
Tax Fees | 478,566 | 352,611 | 189,150 | - | ||||||||||||
|
|
|
| |||||||||||||
$1,239,822 | $1,023,435 | $ | 891,650 | $ | - | |||||||||||
|
|
|
|
Grant Thornton | ||||||||
2021 | 2020 | |||||||
Audit Fees | $ | - | $ | 602,382 | ||||
Audit-Related Fees | - | 77,625 | ||||||
Tax Fees | 326,427 | 475,909 | ||||||
|
|
|
| |||||
$ | 326,427 | $ | 1,155,916 | |||||
|
|
|
|
Audit Fees. Audit fees are the fees billed for professional services rendered by Meridian’s independent registered public accounting firmfirms for their: (i) audit of Meridian’s consolidated annual financial statements for the fiscal years ended September 30, 20182021 and 2017,2020, respectively; (ii) reviews of the unaudited quarterly consolidated financial statements contained in the reports on Form10-Q filed by Meridian during those years; (iii) completion of audits of wholly-owned subsidiaries’ statutory accounts in the United Kingdom, Israel and China during fiscal 20182021 and 2017;2020; and (iv) reporting on Meridian’s internal controls during those years.
Felicia Williams Director since 2018 Age: 56Audit-Related Fees. Audit-related fees are
Felicia Williams serves as Chairwoman of the fees billedAudit Committee. Ms. Williams is currently serving as the Macy’s Inc. Fellow for assuranceCEO Action for Racial Equality, a fellowship that provides the 1,500+ CEO signatories of CEO Action for Diversity & Inclusion with an opportunity to advance racial equity through public policy to address systemic racism and related services that are reasonably relatedsocial injustice and improve societal well-being. Prior to becoming a Fellow, Ms. Williams served as Macy’s Interim Chief Financial Officer and Enterprise Risk Officer from June 2020 to November 2020. Since joining Macy’s in June 2004, Ms. Williams has served as Executive Vice President, Controller and Enterprise Risk Officer (June 2016 – June 2020) and Senior Vice President, Finance and Risk Management (February 2011 – June 2016), as well as in other finance, treasury, risk management and internal audit capacities. Prior to her time at Macy’s, Ms. Williams served in various financial positions at the performanceCoca-Cola Hellenic Bottling Company in Athens, Greece and The Coca-Cola Company in Atlanta, Georgia (June 1994 – June 2004).
Since March 2021, Ms. Williams has served as a director and member of the audit or reviewcommittee of Meridian’sRealogy Holdings Corp. (NYSE:RLGY), a leading provider of U.S. residential real estate services. Ms. Williams brings broad and wide-ranging accounting, finance, treasury and enterprise risk management experience, including analyzing financial statements, including the audit of the Savings and Investment Plan (i.e., the 401K Plan).
Tax Fees. Tax fees are the fees billed for tax return preparation and compliance in Australia, England, Germany and the United States, as well as consultation and research on various matters such as the U.S. tax reform act, state tax issues, international taxcomplex accounting issues and transfer pricing.
The Board recommends that shareholders voteFOR the ratification of appointment of Grant Thornton LLP as Meridian’s independent registered public accountants for the 2019 fiscal year.
As an Ohio corporation, Meridian is governed by the corporate laws of Ohio. Since its common shares are publicly traded on the Nasdaq Global Select Market, and it files reports with the SEC, it is also subject to Nasdaq rules and federal securities laws.
Board Leadership Structure
Governance of the corporation is placed in the hands of the Directors who, in turn, elect officers to manage the business operations. The Board oversees the management of Meridian on your behalf. The Board reviews Meridian’s long-term strategic plans and exercises direct decision making authority in all major decisions, such as acquisitions, the declaration of dividends, major capital expenditures and the establishment of certain company policies.
The Board operates and evaluates its performance in accordance with Corporate Governance Guidelines approved by the Board. These Guidelines are available at our websitewww.meridianbioscience.com.
The Board of Directors is responsible for evaluating and determining Meridian’s leadership structure, and believes that at this point in time separate individuals should serve in the capacities of Chairman of the Board (“Chairman”) and Chief Executive Officer (“CEO”). It is the Board’s belief that such a structure provides the Company with the right foundation to pursue its strategic and operational objectives, while maintaining effective oversight and objective evaluation of the Company’s performance. These key executive positions are held by Mr. David C. Phillips, Chairman of the Board, and Mr. Jack Kenny, CEO. Having served as a Director since 2000, Mr. Phillips was appointed Chairman of the Board upon Mr. John A. Kraeutler retiring from the Company and the Board effective September 30, 2018. In his capacity as Chairman, Mr. Phillips is responsible for: (i) general Board activities, including setting agendas for Board meetings and presiding over all meetings of the Board and shareholders; and (ii) providing advice and counsel to Meridian’s management regarding the Company’s business operations. As CEO, Mr. Kenny is responsible for the general management, oversight, supervision and control of the business affairs of Meridian, and ensuring that all resolutions of the Board are put into effect.
Mr. Phillips was appointed by the Board to serve as Lead Director throughout fiscal 2018, during which time Mr. Kraeutler served as Executive Chairman. As Lead Director, Mr. Phillips’ responsibilities included: (i) in consultation with thenon-management Directors, advising the Chairman as to an appropriate schedule of Board meetings and reviewing and providing the Chairman with input regarding the agendas for each Board meeting; (ii) presiding at all meetings at which the Chairman was not present, including Executive Sessions of thenon-management Directors, and apprising the Chairman of the issues considered thereat; (iii) calling meetings of thenon-management Directors when necessary and appropriate; and (iv) performing such other duties as the Board may from time to time designate. We believe that this leadership structure was the most appropriate for Meridian during fiscal 2018.
In accordance with Nasdaq rules, our Board of Directors affirmatively determines the independence of each Director and nominee for election as a Director in accordance with the elements of independence set forth in the Nasdaq listing standards and Exchange Act rules. Meridian’s Director Independence Standards are available at our websitewww.meridianbioscience.com. Based on these standards, the Board has determined that each of the following members of the Board is independent: James M. Anderson, Dwight E. Ellingwood, John C. McIlwraith, David C. Phillips, John M. Rice, Catherine A. Sazdanoff, and Felicia Williams.
During fiscal 2018, the Board of Directors met on ten occasions. The independent Directors plan to meet as necessary during fiscal 2019 without the presence of management Directors. During fiscal 2018, the independent members of the Board periodically met in executive session without the presence of management Directors following regularly scheduled Board meetings. In addition, there were two meetings of the independent directors during fiscal 2018.
Meridian expects all Directors to attend shareholders’ meetings, and all Directors attended the 2018 Annual Shareholders’ Meeting.
Shareholders may communicate with the full Board or individual Directors on matters concerning Meridian by mail or through our website,www.meridianbioscience.com, in each case to the attention of the Secretary, the address for whom is set forth on page 31 of this proxy statement.
The Board’s Role in Risk Oversight
The Board of Directors, as a whole and also at the Committee level, plays a key role in operational risk oversight at Meridian and works with management to understand the risks the Company faces, the steps that management is taking to manage those risks and the level of risk appropriate for the Company in light of its overall business strategy. The Board approves the high level strategies, financial plans and policies of Meridian, setting the tone and direction for the appropriate levels of risk-taking within the organization.
While overall responsibility for risk oversight rests with the Board, it is the Audit Committee that has been given the primary responsibility of monitoring and evaluating the adequacy of management’s risk assessment and risk management practices. This role is carried out through its charter-mandated responsibilities related to Meridian’s: (i) overall financial risks and exposures; (ii) financial statement risks and exposures; (iii) financial reporting processes; (iv) compliance with ethics policies, such as the Code of Ethics, Employee Complaint Policy, Securities Trading Policies and the Foreign Corrupt Practices Act Policy; and (v) compliance with governmental and legal regulations, including those contained within the Sarbanes-Oxley Act. The Audit Committee provides regular reports to the full Board and works closely with management to update the full Board, as necessary, on matters identified through these Committee risk oversight roles.
The Board has adopted a Code of Ethics applicable to Meridian’s officers, Directors and employees. This Code of Ethics is posted onwww.meridianbioscience.com. To the extent permitted by Nasdaq Marketplace Rule 5610, any amendments to or waivers from the Code of Ethics will be posted on our website within four business days after the date of an amendment.
Committees of the Board of Directors
The Directors have organized themselves into the Committees described below. Each of these Committees has a charter posted onwww.meridianbioscience.com. Meridian does not have an Executive Committee of its Board of Directors. The following table identifies membership and the Chairman of each of the current standing committees of the Board, as well as the number of times each committee met during the fiscal year. In September 2018, Felicia Williams joined the Board and was appointed to the Audit Committee.
Director | Audit | Compensation | Nominating and Corporate Governance | |||
James M. Anderson | Member | Chair | Member | |||
Dwight E. Ellingwood | Chair | |||||
John C. McIlwraith | Member | Member | ||||
David C. Phillips | Chair | Member | ||||
Catherine A. Sazdanoff | Member | |||||
Felicia Williams(1) | Member | |||||
Meetings in Fiscal 2018 | 9 | 7 | 7 |
|
The Audit Committee is comprised of David C. Phillips (Chairman), James M. Anderson, Catherine A. Sazdanoff, and Felicia Williams (effective September 20, 2018). The Committee met nine times during fiscal 2018. Each member is able to read and understand fundamental financial statements. David C. Phillips and Felicia Williams have been designated as Audit Committee financial experts as that term is defined by the SEC.
The Committee oversees the accounting and financial reporting processes of Meridian and the audits of its financial statements by its independent registered public accounting firm. The Committee is solely responsible for the appointment, compensation, retention and oversight of Meridian’s independent registered public accounting firm. The Audit Committee also evaluates information received from Meridian’s independent registered public accounting
firm and management to determine whether the independent registered public accounting firm is independent of management. The independent registered public accounting firm reports directly to the Audit Committee.
In addition, the Audit Committee has established procedures for the receipt, retention and treatment of complaints received by Meridian concerning accounting, internal accounting controls or auditing matters and has established procedures for the confidential and anonymous submission by employees of any concerns they may have regarding questionable accounting or auditing matters.
The Audit Committee, or its Chairman, approves all audit andnon-audit services performed for Meridian by its independent registered public accounting firm before those services are commenced. The Chairman reports to the full Committee at each of its meetings regardingpre-approvals he made since the prior meeting and the Committee approves what he has done between meetings. For these purposes, the Committee or its Chairman is provided with information as to the nature, extent and purpose of each proposed service, as well as the approximate timeframe and proposed cost arrangements for that service.
As previously noted on page 8 in “The Board’s Role in Risk Oversight” section, the Audit Committee also bears certain risk oversight responsibilities.
The Committee has submitted the following report for inclusion in this proxy statement.
On January 24, 2018, the Audit Committee met with representatives of Grant Thornton LLP and Meridian’s internal accountants, at which time the Grant Thornton LLP representatives presented to the Committee the results of their work, including their review of Meridian’s first quarter consolidated financial statements, and discussed their proposed audit fees for fiscal 2018. In addition, the Committee: (i) received an update on controls being put into place to remediate the material weakness in the controls over financial reporting, identified duringwhich qualifies her as an “audit committee financial expert” under SEC guidelines. The Board believes her experience greatly benefits the fiscal 2017 audit (the “2017 material weakness”); (ii) discussed the timing and scope of the planned Sarbanes-Oxley (“SOX”) and internal audit work for fiscal 2018; (iii) received an overview of the new Revenue Recognition Standard, which was effective for the Company October 1, 2018; (iv) received an overview of the anticipated effects of the U.S. Tax and Jobs Act (the “tax reform act”) on the Company; and (v) received an update regarding certain of the Company’s information technology (“IT”) and cyber security endeavors.Company.
On April 24, 2018, the Committee met with representatives of Grant Thornton LLP and Meridian’s internal accountants, at which time the Grant Thornton LLP representatives presented to the Committee the results of their work for their review of Meridian’s second quarter consolidated financial statements and the timing and scope of their engagement for the audit of Meridian’s fiscal 2018 consolidated financial statements. In addition, the Committee received an update on various matters including: (i) SOX work completedto-date by internal audit; (ii) impact of the tax reform act; (iii) the Company’s ongoing cyber security and disaster recovery efforts; (iv) status of the WFOE in China; and (v) status of efforts surrounding preparation to adopt the new Revenue Recognition Standard. The Committee also received an update regarding the successful remediation of the 2017 material weakness.
On July 24, 2018, the Committee met with representatives of Grant Thornton LLP and Meridian’s internal accountants, at which time the Grant Thornton LLP representatives presented to the Committee the results of their work for their review of Meridian’s third quarter consolidated financial statements, including their activities related to their review of the income tax calculation and key accounting matters. Additionally, the Committee received an update on various matters including: (i) SOX work completedto-date by internal audit, including the results of visits to the Company’s locations in the U.K. and Italy, as well the status of certain ITGC testing; (ii) an overview of the Company’s 2018 cyber and IT risk reduction program; (iii) goodwill testing and the reporting units considered for such testing; and (iv) status of activities associated with the planned implementation of the new Revenue Recognition Standard at the beginning of fiscal 2019.
At its meeting on November 6, 2018, the Committee reviewed and discussed with management, Grant Thornton LLP and Meridian’s accounting officers the results of the audit for fiscal 2018, including the financial statements. The Committee discussed with Grant Thornton LLP the matters required to be discussed by Auditing Standards No. 16, as amended (PCAOB Interim Auditing Standard AU Section 380,Communication with Audit Committees). The Grant Thornton LLP representatives reviewed with the Committee written disclosures required by applicable requirements of the PCAOB regarding the independent accountants’ communications with the Audit Committee concerning independence, and presented a letter regarding that matter to the Committee. In concluding that the auditors are independent, we determined, among other things, that thenon-audit services provided by the auditors were compatible with their independence. In addition, the Committee approved related party transactions and approved amendments to the Audit Committee Charter. It also received updates on: (i) IT security; (ii) the results of SOX work; and (iii) implementation of the new Revenue Recognition Standard.
Based on the above mentioned review and discussion of the audited consolidated financial statements, on November 20, 2018, the Committee recommended that the audited consolidated financial statements of Meridian be included in its Annual Report on Form10-K for the year ended September 30, 2018 for filing with the SEC. Similar meetings were held during November 2017 related to the fiscal 2017 audited financial statements.
The remaining meetings throughout fiscal 2018 were held primarily for the purpose of reviewing, discussing and approving the Company’s Quarterly Reports on Form10-Q for filing with SEC.
During its meetings throughout the year, the Committee reviewed and assessed the Company’s financial statements, financial control, financial reporting, and certain legal and regulatory risk exposures, including reviewing procedures related to the receipt, retention and treatment of any complaints concerning accounting, internal accounting controls or auditing matters. Also during its meetings throughout the year, the Chairman of the Audit Committee reported to the full Committee the independent accountants’ fees that had beenpre-approved and the Committee approved such fees. Certain fees werepre-approved by the full Committee. The Committee also reviewed the requirements of and Meridian’s ongoing compliance with Section 404 of the Sarbanes-Oxley Act and conducted a self-assessment, facilitated by a third party.
Respectfully submitted,
Audit Committee
David C. Phillips (Chairman)
James M. Anderson
Catherine A. Sazdanoff
RATIFICATION OF APPOINTMENT OF ERNST & YOUNG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
(Item 2 on the Proxy Card)
Our Audit Committee has appointed Ernst & Young LLP (“Ernst & Young” or “the Firm”) as our independent registered public accounting firm for the fiscal year ending September 30, 2022. In evaluating the appropriateness of engaging Ernst & Young as the Company’s independent registered public accounting firm, the Audit Committee considered a number of factors including, but not limited to: (i) Ernst & Young’s relevant technical expertise and its significant institutional knowledge of the Company’s operations and industry; (ii) the quality and candor of the Firm’s communications with the Audit Committee and management; (iii) the Firm’s independence, including the consideration of any non-audit services provided and their impact on independence; (iv) the quality and efficiency of the services provided, including input from management on the Firm’s performance, objectivity and professional skepticism; (v) external data on audit quality and performance, including recent Public Company Accounting Oversight Board (“PCAOB”) reports on the Firm and its peer firms; (vi) the appropriateness of the Firm’s fees; and (vii) the Firm’s tenure as independent auditors, including the benefits of a longer tenure, and the controls and processes in place that help ensure the Firm’s continued independence. Ernst & Young has served as the Company’s independent registered public accounting firm since December 2020. Our Board has directed that this appointment be submitted to our shareholders for ratification. Although ratification of our appointment of Ernst & Young is not required, we value the opinions of our shareholders and believe that shareholder ratification of our appointment is a good corporate governance practice.
Ernst & Young also served as our independent registered public accounting firm for the fiscal year ended September 30, 2021. Neither the Firm nor any of its members has any direct or indirect financial interest in or any connection with us in any capacity other than as our auditors, providing audit and non-audit related services. A representative of Ernst & Young is expected to virtually attend the Annual Meeting and to have an opportunity to make a statement and be available to respond to appropriate questions from shareholders. In the event that the appointment of Ernst & Young is not ratified by the shareholders, the Audit Committee intends to continue the engagement of Ernst & Young at least through the fiscal year ending September 30, 2022. Even if the appointment of Ernst & Young is ratified, the Audit Committee retains the discretion to appoint a different independent auditor at any time if it determines that such a change is in the interests of the Company.
Recent Change in Accounting Firm
Following a request for proposal (“RFP”) process, effective December 22, 2020 (the “Effective Date”), the Audit Committee of the Board of Directors of Meridian selected Ernst & Young as the Company’s independent registered public accounting firm for the Company’s fiscal year ended September 30, 2021. The Audit Committee dismissed Grant Thornton LLP (“Grant Thornton”), the Company’s then current independent registered public accounting firm, effective as of the Effective Date.
Grant Thornton’s reports on the Company’s Consolidated Financial Statements as of and for the fiscal years ended September 30, 2020 and 2019 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles. During the fiscal years ended September 30, 2020 and 2019, and the subsequent interim period through the Effective Date, there were: (i) no disagreements within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions between the Company and Grant Thornton on any matters of accounting principles or practices, consolidated financial statement disclosure, or auditing scope or procedure which, if not resolved to Grant Thornton’s satisfaction, would have caused Grant Thornton to make reference thereto in their reports; and (ii) no “reportable events” within the meaning of Item 304(a)(1)(v) of Regulation S-K.
The Company requested that Grant Thornton furnish a letter addressed to the SEC stating whether or not it agrees with the above statements, and, if not, stating the respects in which it does not agree. A copy of Grant Thornton’s letter agreeing with the above statements, dated December 28, 2020, was filed as Exhibit 16.1 to Meridian’s Form 8-K filed on or about December 30, 2020.
During the fiscal years ended September 30, 2020 and 2019 and the subsequent interim period through the Effective Date, neither the Company nor anyone on its behalf consulted with Ernst & Young regarding: (i) the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s Consolidated Financial Statements, and neither a written report nor oral advice was provided to the Company that Ernst & Young concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue; (ii) any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions; or (iii) any “reportable event” within the meaning of Item 304(a)(1)(v) of Regulation S-K.
Principal Accounting Firm Fees
Aggregate fees billed to Meridian by Ernst & Young and Grant Thornton for fiscal years 2021 and 2020, as applicable, are listed below:
Ernst & Young | ||||||||
2021 | 2020 | |||||||
Audit Fees | $ | 702,500 | $ | - | ||||
Audit-Related Fees | - | - | ||||||
Tax Fees | 189,150 | - | ||||||
|
|
|
| |||||
$ | 891,650 | $ | - | |||||
|
|
|
|
Grant Thornton | ||||||||
2021 | 2020 | |||||||
Audit Fees | $ | - | $ | 602,382 | ||||
Audit-Related Fees | - | 77,625 | ||||||
Tax Fees | 326,427 | 475,909 | ||||||
|
|
|
| |||||
$ | 326,427 | $ | 1,155,916 | |||||
|
|
|
|
Audit Fees. Audit fees are the fees billed for professional services rendered by Meridian’s independent registered public accounting firms for their: (i) audit of Meridian’s consolidated financial statements for the fiscal years ended September 30, 2021 and 2020, respectively; (ii) reviews of the unaudited quarterly consolidated financial statements contained in the reports on Form 10-Q filed by Meridian during those years; (iii) audits of wholly-owned subsidiaries’ statutory accounts in the United Kingdom, Israel and China during fiscal 2021 and 2020; and (iv) reporting on Meridian’s internal controls during those years.
Felicia Williams
Director since 2018
Age: 56
Felicia Williams serves as Chairwoman of the Audit Committee. Ms. Williams is currently serving as the Macy’s Inc. Fellow for CEO Action for Racial Equality, a fellowship that provides the 1,500+ CEO signatories of CEO Action for Diversity & Inclusion with an opportunity to advance racial equity through public policy to address systemic racism and social injustice and improve societal well-being. Prior to becoming a Fellow, Ms. Williams served as Macy’s Interim Chief Financial Officer and Enterprise Risk Officer from June 2020 to November 2020. Since joining Macy’s in June 2004, Ms. Williams has served as Executive Vice President, Controller and Enterprise Risk Officer (June 2016 – June 2020) and Senior Vice President, Finance and Risk Management (February 2011 – June 2016), as well as in other finance, treasury, risk management and internal audit capacities. Prior to her time at Macy’s, Ms. Williams served in various financial positions at the Coca-Cola Hellenic Bottling Company in Athens, Greece and The Compensation Committee is comprisedCoca-Cola Company in Atlanta, Georgia (June 1994 – June 2004).
Since March 2021, Ms. Williams has served as a director and member of James M. Anderson (Chairman)the audit committee of Realogy Holdings Corp. (NYSE:RLGY), John C. McIlwraitha leading provider of U.S. residential real estate services. Ms. Williams brings broad and David C. Phillipswide-ranging accounting, finance, treasury and enterprise risk management experience, including analyzing financial statements, complex accounting issues and internal controls over financial reporting, which qualifies her as an “audit committee financial expert” under SEC guidelines. The Board believes her experience greatly benefits the Company.
RATIFICATION OF APPOINTMENT OF ERNST & YOUNG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
(Item 2 on the Proxy Card)
Our Audit Committee has appointed Ernst & Young LLP (“Ernst & Young” or “the Firm”) as our independent registered public accounting firm for the fiscal year ending September 30, 2022. In evaluating the appropriateness of engaging Ernst & Young as the Company’s independent registered public accounting firm, the Audit Committee considered a number of factors including, but not limited to: (i) Ernst & Young’s relevant technical expertise and its significant institutional knowledge of the Company’s operations and industry; (ii) the quality and candor of the Firm’s communications with the Audit Committee and management; (iii) the Firm’s independence, including the consideration of any non-audit services provided and their impact on independence; (iv) the quality and efficiency of the services provided, including input from management on the Firm’s performance, objectivity and professional skepticism; (v) external data on audit quality and performance, including recent Public Company Accounting Oversight Board (“PCAOB”) reports on the Firm and its peer firms; (vi) the appropriateness of the Firm’s fees; and (vii) the Firm’s tenure as independent auditors, including the benefits of a longer tenure, and the controls and processes in place that help ensure the Firm’s continued independence. Ernst & Young has served as the Company’s independent registered public accounting firm since December 2020. Our Board has directed that this appointment be submitted to our shareholders for ratification. Although ratification of our appointment of Ernst & Young is not required, we value the opinions of our shareholders and believe that shareholder ratification of our appointment is a good corporate governance practice.
Ernst & Young also served as our independent registered public accounting firm for the fiscal year ended September 30, 2021. Neither the Firm nor any of its members has any direct or indirect financial interest in or any connection with us in any capacity other than as our auditors, providing audit and non-audit related services. A representative of Ernst & Young is expected to virtually attend the Annual Meeting and to have an opportunity to make a statement and be available to respond to appropriate questions from shareholders. In the event that the appointment of Ernst & Young is not ratified by the shareholders, the Audit Committee intends to continue the engagement of Ernst & Young at least through the fiscal year ending September 30, 2022. Even if the appointment of Ernst & Young is ratified, the Audit Committee retains the discretion to appoint a different independent auditor at any time if it determines that such a change is in the interests of the Company.
Recent Change in Accounting Firm
Following a request for proposal (“RFP”) process, effective December 22, 2020 (the “Effective Date”), the Audit Committee of the Board of Directors of Meridian selected Ernst & Young as the Company’s independent registered public accounting firm for the Company’s fiscal year ended September 30, 2021. The Audit Committee dismissed Grant Thornton LLP (“Grant Thornton”), the Company’s then current independent registered public accounting firm, effective as of the Effective Date.
Grant Thornton’s reports on the Company’s Consolidated Financial Statements as of and for the fiscal years ended September 30, 2020 and 2019 did not contain any adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope, or accounting principles. During the fiscal years ended September 30, 2020 and 2019, and the subsequent interim period through the Effective Date, there were: (i) no disagreements within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions between the Company and Grant Thornton on any matters of accounting principles or practices, consolidated financial statement disclosure, or auditing scope or procedure which, if not resolved to Grant Thornton’s satisfaction, would have caused Grant Thornton to make reference thereto in their reports; and (ii) no “reportable events” within the meaning of Item 304(a)(1)(v) of Regulation S-K.
The Company requested that Grant Thornton furnish a letter addressed to the SEC stating whether or not it agrees with the above statements, and, if not, stating the respects in which it does not agree. A copy of Grant Thornton’s letter agreeing with the above statements, dated December 28, 2020, was filed as Exhibit 16.1 to Meridian’s Form 8-K filed on or about December 30, 2020.
During the fiscal years ended September 30, 2020 and 2019 and the subsequent interim period through the Effective Date, neither the Company nor anyone on its behalf consulted with Ernst & Young regarding: (i) the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s Consolidated Financial Statements, and neither a written report nor oral advice was provided to the Company that Ernst & Young concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing, or financial reporting issue; (ii) any matter that was the subject of a disagreement within the meaning of Item 304(a)(1)(iv) of Regulation S-K and the related instructions; or (iii) any “reportable event” within the meaning of Item 304(a)(1)(v) of Regulation S-K.
Principal Accounting Firm Fees
Aggregate fees billed to Meridian by Ernst & Young and Grant Thornton for fiscal years 2021 and 2020, as applicable, are listed below:
Ernst & Young | ||||||||
2021 | 2020 | |||||||
Audit Fees | $ | 702,500 | $ | - | ||||
Audit-Related Fees | - | - | ||||||
Tax Fees | 189,150 | - | ||||||
|
|
|
| |||||
$ | 891,650 | $ | - | |||||
|
|
|
|
Grant Thornton | ||||||||
2021 | 2020 | |||||||
Audit Fees | $ | - | $ | 602,382 | ||||
Audit-Related Fees | - | 77,625 | ||||||
Tax Fees | 326,427 | 475,909 | ||||||
|
|
|
| |||||
$ | 326,427 | $ | 1,155,916 | |||||
|
|
|
|
Audit Fees. Audit fees are the fees billed for professional services rendered by Meridian’s independent registered public accounting firms for their: (i) audit of Meridian’s consolidated financial statements for the fiscal years ended September 30, 2021 and 2020, respectively; (ii) reviews of the unaudited quarterly consolidated financial statements contained in the reports on Form 10-Q filed by Meridian during those years; (iii) audits of wholly-owned subsidiaries’ statutory accounts in the United Kingdom, Israel and China during fiscal 2021 and 2020; and (iv) reporting on Meridian’s internal controls during those years.
Audit-Related Fees. Audit-related fees are the fees billed for assurance and related services that are reasonably related to the performance of the audit or review of Meridian’s consolidated financial statements.
Tax Fees. Tax fees are the fees billed for tax return preparation and compliance in Australia, Canada, China, England, Germany, Israel and the United States, as well as consultation and research on various matters such as the U.S. tax reform act, state tax issues, international tax issues, transfer pricing, and tax planning.
The Board recommends that you vote FOR the ratification of appointment of Ernst & Young LLP as Meridian’s independent registered public accounting firm for the 2022 fiscal year.
ADVISORY VOTE ON COMPENSATION OF NAMED EXECUTIVE OFFICERS (“SAY-ON-PAY” PROPOSAL)
(Item 3 on the Proxy Card)
The Dodd-Frank Wall Street Reform and Consumer Protection Act (“Dodd Frank”), enacted in July 2010, requires that we provide our shareholders with the opportunity to vote to approve, on a non-binding, advisory basis, the compensation of our named executive officers as disclosed in this proxy statement in accordance with the compensation disclosure rules of the Securities and Exchange Commission (“SEC”). Dodd Frank also provides that shareholders periodically be given the opportunity to vote, on a non-binding, advisory basis, for their preference as to how frequently we should seek future advisory votes on the compensation of our named executive officers. This opportunity was provided to our shareholders at our 2018 annual meeting, where over 80% of our voting shareholders voted to hold the “say-on-pay” advisory vote annually, in accordance with the recommendation of our Board of Directors. As a result, we are again holding a say-on-pay advisory vote at our 2022 annual meeting, with the next say-on-pay advisory vote to be held at our 2023 annual meeting.
As described below under the heading “Compensation Discussion and Analysis” beginning on page 17 of this proxy statement, we seek to closely align the interests of our named executive officers with the interests of our shareholders. We structure our programs to discourage excessive risk-taking through a balanced use of compensation vehicles and metrics with an overall goal of delivering sustained long-term shareholder value, while aligning our executives’ interests with those of our shareholders. Further, our programs require that a substantial portion of each named executive officer’s compensation be contingent on delivering performance results that benefit our shareholders. Our compensation programs are designed to reward our named executive officers for the achievement of short-term and long-term strategic and operational goals and the achievement of increased total shareholder return.
The vote on this matter is not intended to address any specific element of compensation; rather, the vote relates to the overall compensation of our named executive officers, as described in this proxy statement in accordance with the compensation disclosure rules of the SEC. The vote is advisory, which means that the vote is not binding on the Company, our Board of Directors or the Compensation Committee. The Board and the Compensation Committee will review and consider the voting results when making future decisions regarding our executive compensation program.
Accordingly, we ask our shareholders to approve, on an advisory basis, the compensation of the named executive officers, as disclosed in this proxy statement pursuant to the compensation disclosure rules of the SEC, including the Compensation Discussion and Analysis, the Summary Compensation Table and the other related tables and disclosure.
The Board recommends that you vote FOR the approval of the compensation of our named executive officers as disclosed in this proxy statement.
As an Ohio corporation, Meridian is governed by the corporate laws of Ohio. Since Meridian’s common shares are publicly traded on the Nasdaq Global Select Market, and it files reports with the SEC, it is also subject to Nasdaq rules and federal securities laws.
Board Leadership Structure
Governance of the Company is placed in the hands of the directors who, in turn, elect officers to manage the business operations. The Board oversees the management of Meridian on your behalf. The Board reviews Meridian’s long-term strategic plans and exercises direct decision making authority in all major decisions, such as acquisitions, the declaration of dividends, major capital expenditures and the establishment of certain company policies.
The Board operates and evaluates its performance in accordance with Corporate Governance Guidelines approved by the Board. These Guidelines are available on our website www.meridianbioscience.com.
The Board is responsible for evaluating and determining Meridian’s leadership structure, and believes that at this point in time separate individuals should serve in the capacities of Chairman of the Board (“Chairman”) and Chief Executive Officer (“CEO”). It is the Board’s belief that such a structure provides the Company with the right foundation to pursue its strategic and operational objectives, while maintaining effective oversight and objective evaluation of the Company’s performance. Mr. Jack Kenny holds the position of CEO. Mr. David C. Phillips holds the position of Chairman of the Board, having served as a director since 2000. However, on November 19, 2022, Mr. Phillips notified the Company of his retirement as a director of the Company effective January 26, 2022. The Board intends to elect a new chairman when Mr. Phillips’ current term expires and will not replace the vacated seat, which will reduce the number of directors to eight (candidates listed above). In his capacity as Chairman, Mr. Phillips has been responsible for: (i) general Board activities, including setting agendas for Board meetings and presiding over all meetings of the Board and shareholders; and (ii) providing advice and counsel to Meridian’s management regarding the Company’s business operations. As CEO, Mr. Kenny is responsible for the general management, oversight, supervision and control of the business affairs of Meridian, and ensuring that all resolutions of the Board are put into effect.
In accordance with Nasdaq rules, our Board of Directors affirmatively determines the independence of each director and nominee for election as a director in accordance with the elements of independence set forth in the Nasdaq listing standards and Exchange Act rules. Meridian’s Director Independence Standards are available at our website www.meridianbioscience.com. Based on these standards, the Board has determined that each of the following members of the Board is independent: James M. Anderson, Anthony P. Bihl, Dwight E. Ellingwood, John C. McIlwraith, David C. Phillips, John M. Rice, Catherine A. Sazdanoff, and Felicia Williams.
During fiscal 2021, the Board of Directors met on 14 occasions. The independent directors plan to meet as necessary during fiscal 2022 without the presence of management directors. During fiscal 2021, the independent directors met five times in executive session without the presence of management directors following regularly scheduled Board meetings. All of our directors attended at least 75% of the aggregate of all Board meetings and all meetings of Committees on which such directors served during fiscal 2021.
Meridian expects all directors to attend shareholders’ meetings, and all directors attended the 2021 Annual Shareholders’ Meeting.
Shareholders may communicate with the full Board or individual directors on matters concerning Meridian by mail or through our website, www.meridianbioscience.com, in each case to the attention of the Vice President, Investor Relations, the address for whom is set forth on page 34 of this proxy statement.
The Board’s Role in Risk Oversight
The Board of Directors, as a whole and also at the Committee level, plays a key role in operational risk oversight at Meridian and works with management to understand the risks the Company faces, the steps that management is taking to manage those risks and the level of risk appropriate for the Company in light of its overall business strategy. The Board approves the high level strategies, financial plans and policies of Meridian, setting the tone and direction for the appropriate levels of risk-taking within the organization.
While overall responsibility for risk oversight rests with the Board, it is the Audit Committee that has been given the primary responsibility of monitoring and evaluating the adequacy of management’s risk assessment and risk management practices. This role is carried out through its charter-mandated responsibilities related to Meridian’s: (i) overall financial risks and exposures; (ii) consolidated financial statement risks and exposures; (iii) financial reporting processes; (iv) compliance with ethics policies, such as the Code of Ethics, Employee Complaint Policy, Securities Trading Policies and the Foreign Corrupt Practices Act Policy; and (v) compliance with governmental and legal regulations, including those contained within the Sarbanes-Oxley Act. The Audit Committee provides regular
reports to the full Board and works closely with management to update the full Board, as necessary, on matters identified through these Committee risk oversight roles.
The Board has adopted a Code of Ethics applicable to Meridian’s officers, directors and employees. This Code of Ethics is posted on www.meridianbioscience.com. Any amendments to or waivers of the Code of Ethics (to the extent permitted by Nasdaq Marketplace Rule 5610) will be posted on our website within four business days after the date of an amendment.
Committees of the Board of Directors
The directors have organized themselves into the standing Committees described below. Each of these Committees has a charter posted on www.meridianbioscience.com. Meridian does not have an Executive Committee of its Board of Directors. The following table identifies membership and the Chairperson of each of the current standing Committees of the Board, as well as the number of times each Committee met during the fiscal year.
Director | Audit | Compensation | Nominating and Corporate Governance | |||
James M. Anderson | Member | Chair | ||||
Anthony P. Bihl | Member | Member | ||||
Dwight E. Ellingwood | Member | |||||
John C. McIlwraith | Member | |||||
David C. Phillips | Ex-Officio | Ex-Officio | Ex-Officio | |||
John M. Rice | Member | |||||
Catherine A. Sazdanoff Felicia Williams | Chair | Chair | ||||
Meetings in Fiscal 2021 | 9 | 10 | 4 |
The Audit Committee is comprised of Felicia Williams (Chair), James M. Anderson, Anthony P. Bihl, and David C. Phillips (Ex-Officio). The Committee met nine times during fiscal 2021. Each member is able to read and understand fundamental financial statements. Felicia Williams has been designated as an Audit Committee financial expert as that term is defined by the SEC.
The Committee oversees the accounting and financial reporting processes of Meridian and the audit of its consolidated financial statements by its independent registered public accounting firm. The Committee is solely responsible for the appointment, compensation, retention and oversight of Meridian’s independent registered public accounting firm. The Audit Committee also evaluates information received from Meridian’s independent registered public accounting firm and management to determine whether the independent registered public accounting firm is independent of management. The independent registered public accounting firm reports directly to the Audit Committee.
In addition, the Audit Committee has established procedures for the receipt, retention and treatment of complaints received by Meridian concerning accounting, internal accounting controls or auditing matters and has established procedures for the confidential and anonymous submission by employees of any concerns they may have regarding questionable accounting or auditing matters.
The Audit Committee, or its Chairwoman, approves all audit and non-audit services performed for Meridian by its independent registered public accounting firm before those services are commenced. The Chairwoman reports to the full Audit Committee at each of its meetings regarding pre-approvals she made since the prior meeting and the Committee approves what she has done between meetings. For these purposes, the Audit Committee or its Chairwoman is provided with information as to the nature, extent and purpose of each proposed service, as well as the approximate timeframe and proposed cost arrangements for that service.
As previously noted on page 10 in “The Board’s Role in Risk Oversight” section, the Audit Committee also bears certain risk oversight responsibilities.
The Audit Committee has submitted the following report for inclusion in this proxy statement:
The Audit Committee oversees Meridian’s financial reporting process on behalf of the Board. Management has the primary responsibility for the consolidated financial statements and the reporting process including the systems of internal controls over financial reporting. As part of the oversight processes, the Audit Committee regularly meets with management of Meridian, Meridian’s independent registered public accounting firm and Meridian’s finance and accounting personnel. The Audit Committee regularly meets with each of these groups separately in closed sessions. Throughout the year, the Audit Committee had full access to management, the independent registered public accounting firm and internal auditor for Meridian. To fulfill its responsibilities, the Audit Committee did, among other things, the following:
(a) | reviewed and discussed Meridian’s audited consolidated financial statements for |
(b) | reviewed management’s representations that the interim and |
(c) | reviewed and discussed with the independent registered public accounting firm the matters
|
(d) | discussed with the independent registered public accounting firm the firm’s independence from management and |
(e) | based on the reviews and discussions with management and the independent registered public accounting firm, the independent registered public accounting firm’s disclosures to the Audit Committee, the representations of management and the report of the
|
The Compensation Committee has reviewed the risk profile of the components of the Company’s executive compensation program, including the performance objectives and target levels used in connection with incentive awards, and has considered the risks a NEO might be incentivized to take with respect to such components. When establishing the mix among these components, the Compensation Committee is careful not to encourage excessive risk taking. Specifically, the performance objectives contained in the Company’s executive compensation programs have been balanced between annual and long-term incentive compensation to ensure that all components are aligned and consistent with our long-term business plan and that our overall mix of stock-based awards has been allocated to promote an appropriate combination of incentive and retention objectives.
The Compensation Committee believes that the Company’s executive compensation program does not incentivize the NEOs to engage in business activities or other behavior that would threaten the value of the Company or the investments of its shareholders.
The Compensation Committee continues to monitor and evaluate on an on-going basis the mix of compensation, especially equity compensation, awarded to the NEOs, and the extent to which such compensation aligns the interests of the NEOs with those of the Company’s shareholders. In connection with this practice, the Compensation Committee has, from time to time, reconsidered the structure of the Company’s executive compensation program and the relative weighting of various compensation elements.
See Executive Summary on page 20 for discussion of base salaries, annual cash-based incentive compensation and long-term stock-based compensation.
Company-Sponsored Benefit and Retirement Plans
Meridian provides Company-sponsored benefit and retirement plans to the NEOs. In general, executives participate in the Company’s benefit and retirement plans on the same basis as other Company employees. The core benefit package includes health, dental, short- and long-term disability, and group term life insurance. Meridian generally provides retirement benefits to executives through qualified (under the Internal Revenue Code) defined contribution plans (401K Plan).
Change in Control Severance Benefits
The Compensation Committee believes that a reasonable level of salary and Company-sponsored benefit protection provides a means of retention and allows the NEOs to remain focused on achievement of Company goals and objectives in the event that the Company becomes subject to a merger or acquisition transaction. This component of compensation would only be paid in the event of a change in control of the Company, under certain qualifying conditions, and termination of the NEO’s employment (i.e., double trigger). For the CEO and the NEOs, this component of compensation would include two years’ base salary, performance bonus and core benefits. See page 32 for a description of change in control severance agreements entered into with our executive officers.
Jack Kenny Employment Agreement
On November 5, 2019, Meridian entered into an Amended and Restated Employment Agreement (the “Kenny Employment Agreement”) with Jack Kenny, its CEO. Under the Kenny Employment Agreement, Mr. Kenny is entitled to be paid a base salary of $670,000 and his salary shall be reviewed annually by the Compensation Committee. During the first year of the Kenny Employment Agreement, Mr. Kenny was eligible to earn an annual target bonus of seventy-five percent (75%) of his base salary. Thereafter, the Compensation Committee shall set an eligible target amount for the annual bonus for the applicable employment term year. For fiscal 2022, the target bonus has been set at ninety-five percent (95%) of base salary. The actual amount of any annual bonus payable to Mr. Kenny in any year shall be determined by the Compensation Committee based upon performance criteria set forth in advance under the bonus plan established by the Compensation Committee and the achievement of such performance criteria.
The effective date of the Kenny Employment Agreement is October 1, 2019 and its term is two years, with annual renewal provisions following the initial term. Either the Company or Mr. Kenny may terminate the Kenny Employment Agreement at any time for any reason upon 90 days’ notice. In the event that the Company terminates the employment of Mr. Kenny without Cause or if he terminates his employment for Good Reason, each as defined in the Kenny Employment Agreement, Mr. Kenny is entitled to a severance payment equal to twelve months of his then current base salary plus a pro-rata portion of the target bonus through the date of termination. If such termination occurs during a change in control period (i.e., a double trigger), Mr. Kenny is entitled to a severance payment equal to two times his then current base salary plus his target bonus for the year in which the termination occurs.
The Kenny Employment Agreement contains customary indemnification provisions and a “clawback” provision that enables the Company to recoup any amounts paid to Mr. Kenny under the Kenny Employment Agreement if so required by applicable law or any applicable securities exchange listing standards.
Internal Pay Equity
The Compensation Committee believes that the relative difference between the CEO’s compensation and the compensation of the Company’s other executives is appropriate. Further, the Compensation Committee believes that the Company’s internal pay equity structure is appropriate based upon the contributions to the success of the Company and as a means of motivation to other executives and employees.
The Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K with management. Based on these reviews and discussions, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in the Company’s proxy statement on Schedule 14A.
Members of the Compensation Committee
James M. Anderson (Chair)
Anthony P. Bihl
John C. McIlwraith
David C. Phillips (Ex-Officio)
Our CEO Pay Ratio was calculated in compliance with the requirements set forth in Item 402(u) of Regulation S-K. We identified the median employee population as of July 31, 2021, which included all 730 global full-time, part-time, temporary and seasonal employees employed on that date, excluding 26 such employees in our Belgium, China, France and Holland locations, which in the aggregate represent less than 5% of our workforce. We used a consistently applied compensation measure across our global employee population to calculate the median employee compensation. For our consistently applied compensation measure, we utilized total cash compensation per our internal payroll records, annualized and translated to U.S. dollars. We then calculated the median employee’s fiscal 2021 compensation in the same manner as the NEOs in the Summary Compensation Table. Our median employee compensation for fiscal 2021 was $71,837 and our CEO’s compensation was $3,233,705. Accordingly, our CEO-to-Employee Pay Ratio is approximately 45:1.
The following table summarizes the aggregate compensation paid, or earned, by each of the NEOs for the fiscal years ended September 30, 2021, 2020 and 2019, respectively:
Name and Principal Position | Year | Salary | Bonus1 | Stock Awards2 | Option Awards3 | Non-Equity | Change in Pension Value and Nonqualified Deferred Compensation Earnings | All Other | Total | ||||||||||||||||||||||||||||||||||||
(a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | (i) | |||||||||||||||||||||||||||||||||||||
Jack Kenny | 2021 | $ | 690,000 | - | $ | 1,035,000 | $ | 690,000 | $ | 800,000 | - | $ | 18,705 | $ | 3,233,705 | ||||||||||||||||||||||||||||||
Chief Executive Officer | 2020 | $ | 670,000 | - | $ | 1,005,000 | $ | 670,000 | $ | 958,770 | - | $ | 26,714 | $ | 3,330,484 | ||||||||||||||||||||||||||||||
2019 | $ | 650,000 | - | $ | 485,250 | - | $ | 150,000 | - | $ | 31,142 | $ | 1,316,392 | ||||||||||||||||||||||||||||||||
Bryan T. Baldasare6 | |||||||||||||||||||||||||||||||||||||||||||||
Executive Vice President, | 2021 | $ | 388,332 | - | $ | 200,000 | $ | 100,000 | $ | 245,604 | - | $ | 18,705 | $ | 952,641 | ||||||||||||||||||||||||||||||
Chief Financial Officer | 2020 | $ | 377,831 | - | $ | 201,028 | - | $ | 290,016 | - | $ | 33,749 | $ | 902,624 | |||||||||||||||||||||||||||||||
and Secretary | 2019 | $ | 283,039 | - | $ | 157,563 | - | $ | 28,600 | - | $ | 21,557 | $ | 490,759 | |||||||||||||||||||||||||||||||
Lourdes G. Weltzien | 2021 | $ | 383,847 | - | $ | 225,000 | $ | 100,000 | $ | 263,106 | - | $ | 18,705 | $ | 990,658 | ||||||||||||||||||||||||||||||
Executive Vice President, | 2020 | $ | 368,711 | - | $ | 201,028 | - | $ | 283,625 | - | $ | 31,172 | $ | 884,536 | |||||||||||||||||||||||||||||||
Life Science | 2019 | $ | 358,431 | - | $ | 242,625 | - | $ | 50,512 | - | $ | 23,982 | $ | 675,550 | |||||||||||||||||||||||||||||||
Tony Serafini-Lamanna7 | 2021 | $ | 367,891 | - | $ | 200,000 | $ | 100,000 | $ | 214,137 | - | $ | 18,498 | $ | 900,526 | ||||||||||||||||||||||||||||||
Executive Vice President, | 2020 | $ | 317,269 | $ | 30,000 | $ | 120,613 | $ | 10,328 | $ | 274,752 | - | $ | 32,979 | $ | 785,941 | |||||||||||||||||||||||||||||
Diagnostics | 2019 | $ | 274,346 | - | $ | 157,563 | - | $ | 28,700 | - | $ | 76,921 | $ | 537,530 |
1 The amount reflected for Mr. Serafini-Lamanna represents an amount received in connection with retention bonus payments made to the Executive Leadership Team in March 2020, prior to his promotion to Executive Vice President. No such payments were made to Mr. Kenny, Mr. Baldasare or Dr. Weltzien. See Note 7 below.
2 The amounts shown reflect the grant date fair value of the restricted stock units issued during fiscal years 2021, 2020 and 2019 in accordance with ASC Topic 718, including those granted to Mr. Kenny in connection with his November 5, 2019 Employment Agreement. In addition, the amounts reflected for Mr. Baldasare and Mr. Serafini-Lamanna in fiscal 2019 include the grant date fair value of restricted stock units granted in connection with the acquisition of GenePOC, Inc. A discussion of the assumptions used in calculating these values may be found in Note 12(b) on page 67 of the Company’s Annual Report on Form 10-K filed with the SEC on November 23, 2021.
3 The amounts shown reflect the grant date fair value of the stock options granted during fiscal years 2021 and 2020 in accordance with ASC Topic 718, including those granted to: (i) Mr. Kenny in connection with his
November 5, 2019 Employment Agreement; and (ii) Mr. Serafini-Lamanna in connection with retention grants made to members of the Executive Leadership Team, excluding Mr. Kenny, Mr. Baldasare and Dr. Weltzien, in March 2020, prior to his promotion to Executive Vice President. A discussion of the assumptions used in calculating these values may be found in Note 12(b) on page 67 of the Company’s Annual Report on Form 10-K filed with the SEC on November 23, 2021.
4 The amounts shown represent amounts earned by the NEOs pursuant to the Officer’s Performance Compensation Plan for fiscal 2021, 2020 and 2019.
5 The amounts shown represent Retirement Contributions made by the Company on behalf of the NEOs.
6 Mr. Baldasare was named Executive Vice President and Chief Financial Officer of Meridian effective October 1, 2019.
7 Mr. Serafini-Lamanna was named Executive Vice President, Diagnostics effective May 18, 2020.
The following table sets forth, for each of the NEOs, information related to grants made during fiscal 2021 under Meridian’s Cash-Based Incentive Compensation Plan and 2012 Stock Incentive Plan:
Name | Grant Date | Estimated Future Payouts Under Non- Equity Incentive Plan Awards1 | Estimated Future Payouts Under Equity Incentive Plan Awards | All other Stock Awards: Number of Shares of Stock or Units (#) | All other Option Awards: Number of Securities Underlying Options (#) | Exercise or Base Price of Option Awards ($/Sh) | Grant Date of Stock and Option | |||||||||||||||||
Threshold ($) | Target ($) | Max ($) | Threshold (#) | Target (#) | Max (#) | |||||||||||||||||||
(a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | (i) | (j) | (k) | (l) | |||||||||||||
Jack Kenny | | 11/05/20 11/05/20 |
| $124,218 - | $621,090 - | $1,055,853 - | - - | - - | - - | - 56,0062 | - 83,5353 | - - | - $1,725,000 | |||||||||||
Bryan T. Baldasare | | 11/05/20 11/05/20 |
| $ 39,140 - | $195,700 - | $332,690 - | - - | - - | - - | - 10,8232 | - 12,1073 | - - | - $ 300,000 | |||||||||||
Lourdes G. Weltzien | | 11/05/20 11/05/20 |
| $ 38,835 - | $194,174 - | $330,096 - | - - | - - | - - | - 12,1752 | - 12,1073 | - - | - $ 325,000 | |||||||||||
Tony Serafini-Lamanna | | 11/05/20 11/05/20 |
| $ 37,080 - | $185,400 - | $315,180 - | - - | - - | - - | - 10,8232 | - 12,1073 | - - | - $ 300,000 |
1 These columns reflect the potential payout for each NEO under the fiscal 2021 CICP if the threshold, target and maximum goals, as initially established, were satisfied for all performance measures.
2 This grant of time-based restricted stock units vests 100% on November 15, 2023.
3 This grant of time-based stock options vests 100% on November 15, 2023.
OUTSTANDING EQUITY AWARDS AT FISCAL YEAR-END
The following table provides information on the NEOs’ holdings of equity awards under Meridian’s 2021 Omnibus Award Plan and 2012 Stock Incentive Plan as of September 30, 2021:
Option Awards | Stock Awards | ||||||||||||||||||||||||||||||||||||||||||||
Name | Number of Securities Underlying Unexercised Options (#) Exercisable | Number of Securities Underlying Unexercised Options (#) Unexercisable | Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) | Option Exercise Price ($) | Option Expiration Date | Number of Shares or Units of Stock That Have Not Vested (#) | Market Value of Shares or Units of Stock That Have Not Vested ($) | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | ||||||||||||||||||||||||||||||||||||
(a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | (i) | (j) | ||||||||||||||||||||||||||||||||||||
Jack Kenny | 25,000 | 1 | 25,000 | 1 | - | $ | 14.50 | 10/09/27 | - | - | - | - | |||||||||||||||||||||||||||||||||
23,564 | 2 | 132,078 | 2 | - | $ | 10.10 | 11/05/29 | - | - | - | - | ||||||||||||||||||||||||||||||||||
- | 83,535 | 3 | - | $ | 18.48 | 11/05/30 | - | - | - | - | |||||||||||||||||||||||||||||||||||
25,000 | 9 | $ | 481,000 | - | - | ||||||||||||||||||||||||||||||||||||||||
25,000 | 9 | $ | 481,000 | - | - | ||||||||||||||||||||||||||||||||||||||||
99,505 | 10 | $ | 1,914,476 | - | - | ||||||||||||||||||||||||||||||||||||||||
56,006 | 13 | $ | 1,077,555 | - | - | ||||||||||||||||||||||||||||||||||||||||
Bryan T. Baldasare | - | 12,107 | 3 | - | $ | 18.48 | 11/05/30 | - | - | - | - | ||||||||||||||||||||||||||||||||||
5,000 | 9 | $ | 96,200 | - | - | ||||||||||||||||||||||||||||||||||||||||
7,500 | 9 | $ | 144,300 | - | - | ||||||||||||||||||||||||||||||||||||||||
1,200 | 11 | $ | 23,088 | - | - | ||||||||||||||||||||||||||||||||||||||||
20,534 | 12 | $ | 395,075 | - | - | ||||||||||||||||||||||||||||||||||||||||
10,823 | 13 | $ | 208,235 | - | - | ||||||||||||||||||||||||||||||||||||||||
Lourdes G. Weltzien | 10,000 | 4 | - | - | $ | 19.66 | 07/01/26 | - | - | - | - | ||||||||||||||||||||||||||||||||||
- | 12,500 | 5 | - | $ | 14.65 | 11/08/27 | - | - | - | - | |||||||||||||||||||||||||||||||||||
7,500 | 6 | 2,500 | 6 | - | $ | 14.30 | 04/24/28 | - | - | - | - | ||||||||||||||||||||||||||||||||||
- | 12,107 | 3 | - | $ | 18.48 | 11/05/30 | - | - | - | - | |||||||||||||||||||||||||||||||||||
7,274 | 9 | $ | 139,952 | - | - | ||||||||||||||||||||||||||||||||||||||||
12,123 | 9 | $ | 233,247 | - | - | ||||||||||||||||||||||||||||||||||||||||
19,915 | 12 | $ | 383,165 | - | - | ||||||||||||||||||||||||||||||||||||||||
11,808 | 13 | $ | 227,186 | - | - | ||||||||||||||||||||||||||||||||||||||||
Tony Serafini- | - | 10,000 | 7 | - | $ | 14.60 | 04/30/28 | - | - | - | - | ||||||||||||||||||||||||||||||||||
Lamanna | - | 4,000 | 8 | - | $ | 6.97 | 03/26/30 | - | - | - | - | ||||||||||||||||||||||||||||||||||
- | 12,107 | 3 | - | $ | 18.48 | 11/05/30 | - | - | - | - | |||||||||||||||||||||||||||||||||||
7,500 | 9 | $ | 144,300 | - | - | ||||||||||||||||||||||||||||||||||||||||
1,200 | 11 | $ | 23,088 | - | - | ||||||||||||||||||||||||||||||||||||||||
12,320 | 12 | $ | 237,037 | - | - | ||||||||||||||||||||||||||||||||||||||||
10,823 | 13 | $ | 208,235 | - | - |
1 Options vest in four equal annual installments from the date of grant, until fully vested on October 9, 2021.
2 Options vest in three equal annual installments from the date of grant, until fully vested on October 1, 2022.
3 Options vest in full on November 15, 2023.
4 Options fully vested on July 1, 2020.
5 Options vest in full on November 8, 2021.
6 Options vest in four equal annual installments from the date of grant, until fully vested on April 24, 2022.
7 Options vest in full on April 30, 2022.
8 Options vest in full on March 26, 2023.
9 Units vest on November 15, 2021.
10 Units vest on October 1, 2022.
11 Units vest on September 16, 2022.
12 Units vest on November 15, 2022.
13 Units vest on November 15, 2023.
OPTION EXERCISES AND STOCK VESTED
The following table sets forth, for each of the NEOs, information on options exercised and restricted stock units vested during fiscal 2021:
Option Awards | Stock Awards | |||||||||||||||
Name | Number of Shares Acquired on Exercise (#) | Value Realized on Exercise ($)1 | Number of Shares Acquired on Vesting (#) | Value Realized on Vesting ($)2 | ||||||||||||
(a) | (b) | (c) | (d) | (e) | ||||||||||||
| ||||||||||||||||
Jack Kenny | 92,477 | $ | 1,614,455 | - | $ | - | ||||||||||
Bryan T. Baldasare | 15,000 | $ | 117,225 | 5,000 | $ | 84,600 | ||||||||||
Lourdes G. Weltzien | - | $ | - | 12,214 | 3 | $ | 212,871 | |||||||||
Tony Serafini-Lamanna | - | $ | - | - | $ | - |
1 Amounts reflect the difference between the exercise price of the option and the market price of Meridian common shares at the time of exercise.
2 Amounts reflect the market price of Meridian common shares at the time of restricted stock units vesting.
3 Included in these restricted stock units are the following restricted stock units that were withheld by the Company under the net share settlement method to cover certain taxes due upon Dr. Weltzien becoming retirement eligible: (i) 226 granted November 8, 2017; (ii) 377 granted November 15, 2018; (iii) 619 granted October 31, 2019; and (iv) 367 granted November 5, 2020. The value realized related to these withheld restricted stock units totaled $31,796 and is included within the total reflected in the table above.
Our 401(k) Savings Plan (“401(k) Plan”) allows all U.S. employees of the Company as soon as administratively possible following their employment to set aside a portion of their compensation each year for their retirement needs, up to the limits set by the Internal Revenue Code. Presently, the Company contributes a matching contribution of 100% of the first 4% of the employee’s contribution (i.e., up to 4% of an employee’s salary), subject to Internal Revenue Code limitations. The Company may also contribute a profit-sharing contribution at its discretion. Employee contributions and employer matching contributions are 100% vested immediately. Participants are entitled to direct the investment of their accounts among various mutual funds selected by the Meridian Bioscience, Inc., Savings and Investment Plan Committee. Participants who terminate employment are entitled to receive the vested portion of their accounts.
POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL
As described on page 27 in the “Compensation Discussion and Analysis” section of this proxy statement, Mr. Kenny and Meridian are parties to the Kenny Employment Agreement which sets forth compensation, non-competition, benefit and severance provisions and provides for a payment equal to twelve months of Mr. Kenny’s then current base salary plus a pro-rata portion of the target bonus through the date of termination in the event Mr. Kenny is terminated by Meridian without cause or Mr. Kenny terminates his employment for good reason. If such termination occurs during a change in control period (double trigger), Mr. Kenny is entitled to a severance payment equal to two times his then current base salary plus his target bonus for the severance period.
Had one of the events noted above occurred on September 30, 2021 and Meridian been within a change in control of the Company, under certain qualifying conditions, and termination of the NEO’s employment (double trigger). For the CEO and other NEOs, this component of compensation would include two years’ base salary, performance bonus and core benefits. See page 28 for a description of change in control severance agreements entered into with our Executive Officers.
Jack Kenny Employment Agreement
Effective October 9, 2017, the Company and Mr. Kenny entered into an Employment Agreement (the “Kenny Employment Agreement”) providing for the terms of Mr. Kenny’s employment as Chief Executive Officer. The Kenny Employment Agreement provides that Mr. Kenny is entitled to receive a base salary of $550,000 for the first year of the Kenny Employment Agreement’s term (“Year 1”) and $650,000 for the second year of the Kenny Employment Agreement’s term (“Year 2”). Mr. Kenny is eligible to earn an annual bonus of up to $275,000 for Year 1 and $325,000 for Year 2, subject to the achievement of certain performance criteria as determined by the Compensation Committee of the Board. The Kenny Employment Agreement also provides that Mr. Kenny receive: (i) a grant of stock options to purchase 100,000 shares of common stock which will vest on apro-rata basis over four (4) years following the effective date of the Kenny Employment Agreement; and (ii) a grant of 13,000 restricted stock units vesting in a lump sum or “cliff” basis on the second anniversary of the effective date of the Kenny Employment Agreement. The Kenny Employment Agreement also provides that Mr. Kenny receive an annual equity award of no less than 25,000 restricted stock units per year.
The Kenny Employment Agreement’s term continues through October 9, 2019, and thereafter provides for renewal periods of one (1) year that automatically renew on the annual anniversary of the effective date of the Kenny Employment Agreement. Pursuant to the terms of the Kenny Employment Agreement, there is no required minimum period of employment and either the Company or Mr. Kenny may terminate his employment under the Kenny Employment Agreement at any time for any reason or no reason. If Mr. Kenny terminates the Kenny Employment Agreement, he must give the Company at least 90 days’ prior written notice. If the Company terminates the Kenny Employment Agreement without Cause, the Company is obligated to give Mr. Kenny 90 days’ prior written notice. In the event that the Company terminates the employment of Mr. Kenny without Cause or if he terminates his employment for Good Reason, each as defined in the Kenny Employment Agreement, Mr. Kenny is entitled to a severance payment equal to twelve months of his then current base salary plus apro-rata portion of the target bonus through the date of termination. If such termination occurs during a change of control period (double trigger), Mr. Kenny is entitled to a severance payment equal to two times his then current base salary plus his target bonus for the severance period.
John A. Kraeutler Employment Agreement and Supplemental Benefit Agreement
Effective October 3, 2016, the Company and Mr. Kraeutler entered into a Third Amended and Restated Employment Agreement (the “Kraeutler Employment Agreement”), which, among other things, extended the term of his employment and incorporated the terms and conditions of his Supplemental Benefit Agreement. The Kraeutler Employment Agreement provided that Mr. Kraeutler was entitled to receive an established minimum annual salary and that he was eligible to participate in the Company’s cash-based and stock-based incentive plans. The Kraeutler Employment Agreement also provided that Mr. Kraeutler receive: (i) a grant of 50,000non-qualified stock options vesting on September 30, 2017 and a grant of 50,000non-qualified stock options vesting on September 30, 2018 so long as he was employed on that date; and (ii) two grants of 25,000 performance-based restricted stock units, with one grant to be earned if fiscal 2017 revenue and earnings guidance was achieved, and the other grant to be earned if fiscal 2018 revenue and earnings guidance was achieved. As a result of the fiscal 2018 revenue and earnings guidance being achieved, 25,000 restricted stock units granted under the Kraeutler Employment Agreement have
fully vested. However, as a result of fiscal 2017 revenue and earnings guidance not being achieved, 25,000 restricted stock units granted under the Kraeutler Employment Agreement were not earned and have been cancelled.
Pursuant to his Second Amended and Restated Employment Agreement, effective from January 15, 2015 to October 3, 2016 (the “2015 Employment Agreement”) and which was replaced by the Kraeutler Employment Agreement, Mr. Kraeutler earned 50,000non-qualified stock options as a result of being employed by the Company as of September 30, 2016. However, as a result of fiscal 2016 revenue and earnings guidance not being achieved, 25,000 restricted stock units granted under the 2015 Employment Agreement were not earned and have been cancelled.
In addition, the Kraeutler Employment Agreement provides that Mr. Kraeutler is eligible to receive:
Post-retirement benefit payments totaling $1,200,000, payable in one hundred twenty (120) monthly payments of $10,000; and
Lifetime insurance benefits including health insurance and comprehensive long-term care insurance.
The Kraeutler Employment Agreement’s term extended through September 30, 2018, and included provisions for a12-month consulting arrangement following that date.
Lueke Consulting Agreement
The Company and Ms. Lueke have entered into a Consulting Agreement effective January 1, 2019 upon her retirement from the Company. The Consulting Agreement provides that Ms. Lueke will assist the Company on anas-requested basis with matters related to the Company’s financial reporting and accounting, among other matters. Under the Consulting Agreement, the Company agreed to pay Ms. Lueke $90,000 per year and reimburse her for certain expenses. The Consulting Agreement’s term is three years and may be renewed upon mutual written agreement or cancelled by Ms. Lueke at any time.
Internal Pay Equity
The Compensation Committee believes that the relative difference between the CEO’s compensation and the compensation of the Company’s other executives has not increased significantly over the years. Further, the Compensation Committee believes that the Company’s internal pay equity structure is appropriate based upon the contributions to the success of the Company and as a means of motivation to other executives and employees.
The Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of RegulationS-K with management. Based on these reviews and discussions, the Compensation Committee recommended to the Board of Directors that the Compensation Discussion and Analysis be included in the Company’s proxy statement on Schedule 14A.
Members of the Compensation Committee
James M. Anderson (Chairman)
John C. McIlwraith
David C. Phillips
Our CEO Pay Ratio was calculated in compliance with the requirements set forth in Item 402(u) of RegulationS-K. We identified the median employee population as of July 31, 2018, which included all 618 global full-time, part-time, temporary and seasonal employees employed on that date, excluding 26 such employees in our Belgium, China, France, Holland and Singapore locations, which in the aggregate represent less than 5% of our workforce. We used a consistently applied compensation measure across our global employee population to calculate the median employee compensation. For our consistently applied compensation measure, we utilized total cash
compensation per our internal payroll records, annualized and translated to U.S. dollars. We then calculated the median employee’s fiscal 2018 compensation in the same manner as the named executive officers in the Summary Compensation Table. Our median employee compensation for fiscal 2018 was $71,983 and our Chief Executive Officer’s compensation was $1,858,606. Accordingly, ourCEO-to-Employee Pay Ratio is 26:1 (17:1 upon excluding certainone-time compensation components related to our CEO’s hiring in October 2017, as disclosed within this proxy statement).
The following table summarizes the aggregate compensation paid, or earned, by each of the NEOs for the fiscal years ended September 30, 2018, 2017 and 2016, respectively:
| ||||||||||||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
| |||||||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
All Other Compensation | ||||||||||||||||||||||||||||
Jack Kenny | Melissa A. Lueke | John A. Kraeutler | Lawrence J. Baldini | Susan D. Rolih | Richard L. Eberly | Marco G. Calzavara | ||||||||||||||||||||||
Retirement Contributions | $ | 11,846 | $ | 16,771 | $ | 17,529 | $ | 19,774 | $ | 19,394 | $ | 8,406 | $ | 26,012 | ||||||||||||||
Relocation Costs, IncludingGross-up | 148,962 | — | — | — | — | — | — | |||||||||||||||||||||
Restricted Stock Dividends | 31,500 | 22,000 | 62,500 | 22,000 | 22,000 | 11,000 | 13,255 | |||||||||||||||||||||
Auto Lease / Auto Allowance | — | — | 11,552 | — | — | 5,023 | 3,815 | |||||||||||||||||||||
Insurance Premiums, IncludingGross-up | — | — | 60,624 | — | — | — | — | |||||||||||||||||||||
Separation Payment | — | — | — | — | — | 1,137,810 | 871,279 | |||||||||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||||||||||
Totals | $ | 192,308 | $ | 38,771 | $ | 152,205 | $ | 41,774 | $ | 41,394 | $ | 1,162,239 | $ | 914,361 | ||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The following table sets forth, for each of the NEOs, information related to grants made during fiscal 2018 under Meridian’s 2012 Stock Incentive Plan:
Estimated Future Payouts Under Non-Equity Incentive Plan Awards1 | Estimated Future Payouts Under Equity Incentive Plan Awards | All other Stock Awards: Number of Shares of Stock or Units (#) | All other Option Awards: Number of Securities Underlying Options (#) | Exercise or Base Price of Option Awards ($/Sh) | Grant Date Fair Value of Stock and Option Awards | |||||||||||||||||||||||||||||||||||||||
Name | Grant Date | Threshold ($) | Target ($) | Max ($) | Threshold (#) | Target (#) | Max (#) | |||||||||||||||||||||||||||||||||||||
(a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | (i) | (j) | (k) | (l) | |||||||||||||||||||||||||||||||||
Jack Kenny | | 10/09/17 11/08/17 |
| $ | — 96,250 |
| $ | — 192,500 |
| $ | — 275,000 |
| | — — |
| | — — |
| | — — |
| | 13,000 25,000 | 2 3 | | 100,000 — | 2
| $
| 14.50 — |
| $ $ | 507,640 366,250 |
| |||||||||||
Melissa A. Lueke | 11/08/17 | $ | 60,200 | $ | 120,400 | $ | 180,600 | — | — | — | 7,500 | 3 | 12,500 | 3 | $ | 14.65 | $ | 150,181 | ||||||||||||||||||||||||||
John A. Kraeutler | | 10/02/17 11/08/17 |
| $ | — 114,891 |
| $ | — 229,781 |
| $ | — 344,672 |
| | — — |
| | — — |
| | — — |
| | 25,000 25,000 | 4 3 | | — — |
| | — — |
| $ $ | 382,500 366,250 |
| |||||||||||
Lawrence J. Baldini | 11/08/17 | $ | 61,636 | $ | 123,272 | $ | 184,908 | — | — | — | 7,500 | 3 | 12,500 | 3 | $ | 14.65 | $ | 150,181 | ||||||||||||||||||||||||||
Susan D. Rolih | 11/08/17 | $ | 59,682 | $ | 119,364 | $ | 179,046 | — | — | — | 7,500 | 3 | 12,500 | 3 | $ | 14.65 | $ | 150,181 | ||||||||||||||||||||||||||
Richard L. Eberly | 11/08/17 | — | — | — | — | — | — | 7,500 | 3 | 12,500 | 3 | $ | 14.65 | $ | 150,181 | |||||||||||||||||||||||||||||
Marco G. Calzavara | 11/08/17 | — | — | — | — | — | — | 8,000 | 3 | — | — | $ | 117,200 |
|
|
|
|
OUTSTANDING EQUITY AWARDS AT FISCALYEAR-END
The following table provides information on the NEOs’ holdings of equity awards under Meridian’s 2012 Stock Incentive Plan and 2004 Equity Compensation Plan as of September 30, 2018:
Option Awards | Stock Awards | |||||||||||||||||||||||||||||||||||
Name | Number of Securities Underlying Unexercised Options (#) Exercisable | Number of Securities Underlying Unexercised Options (#) Unexercisable | Equity Incentive Plan Awards: Number of Securities Underlying Unexercised Unearned Options (#) | Option Exercise Price ($) | Option Expiration Date | Number of Shares or Units of Stock That Have Not Vested (#) | Market Value of Shares or Units of Stock That Have Not Vested ($) | Equity Incentive Plan Awards: Number of Unearned Shares, Units or Other Rights That Have Not Vested (#) | Equity Incentive Plan Awards: Market or Payout Value of Unearned Shares, Units or Other Rights That Have Not Vested ($) | |||||||||||||||||||||||||||
(a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | (i) | (j) | |||||||||||||||||||||||||||
Jack Kenny | — | 100,0001 | — | $ | 14.50 | 10/09/27 | | — 13,00010 25,00011 |
| $ $ | — 193,700 372,500 |
| | — — — |
| | — — — |
| ||||||||||||||||||
Melissa A. Lueke | | 6,2502 2,5003 — |
| | 6,2502 7,5003 12,5004 |
| | — — — |
| $ $ $ | 19.56 16.85 14.65 |
| | 03/24/26 11/16/26 11/08/27 |
| | — — — 9,00012 10,00013 10,00014 7,50011 |
| $ $ $ $ | — — — 134,100 149,000 149,000 111,750 |
| | — — — — — — — |
| | — — — — — — — |
| |||||||||
John A. Kraeutler | | 100,0005 15,0002 100,0006 |
| | — — — |
| | — — — |
| $ $ $ | 16.50 19.56 19.09 |
| | 09/30/21 12/30/18 09/30/21 |
| | — — — |
| | — — — |
| | — — — |
| | — — — |
| |||||||||
Lawrence J. Baldini | | 5007 1,0002 6,7008 — |
| | — 1,0002 3,3008 12,5004 |
| | — — — — |
| $ $ $ $ | 19.71 19.56 20.41 14.65 |
| | 08/04/20 03/24/26 03/28/26 11/08/27 |
| | — — — — 9,00012 10,00013 10,00014 7,50011 |
| $ $ $ $ | — — — — 134,100 149,000 149,000 111,750 |
| | — — — — — — — — |
| | — — — — — — — — |
| |||||||||
Susan D. Rolih | | 1,2007 5,0009 5002 2,5003 — |
| | — — 5002 7,5003 12,5004 |
| | — — — — — |
| $ $ $ $ $ | 19.71 21.75 19.56 16.85 14.65 |
| | 08/04/20 07/01/23 03/24/26 11/16/26 11/08/27 |
| | — — — — — 9,00012 10,00013 10,00014 7,50011 |
| $ $ $ $ | — — — — — 134,100 149,000 149,000 111,750 |
| | — — — — — — — — — |
| | — — — — — — — — — |
| |||||||||
Richard L. Eberly | — | — | — | — | — | — | — | — | — | |||||||||||||||||||||||||||
Marco G. Calzavara | — | — | — | — | — | — | — | — | — |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
OPTION EXERCISES AND STOCK VESTED
The following table sets forth, for each of the NEOs, information on options exercised and restricted stock units vested during fiscal 2018:
Option Awards | Stock Awards | |||||||||||||||
Name | Number of Shares Acquired on Exercise (#) | Value Realized on Exercise ($)1 | Number of Shares Acquired on Vesting (#) | Value Realized on Vesting ($)2 | ||||||||||||
(a) | (b) | (c) | (d) | (e) | ||||||||||||
Jack Kenny | — | $ | — | — | $ | — | ||||||||||
Melissa A. Lueke | — | $ | — | 9,000 | $ | 134,550 | ||||||||||
John A. Kraeutler | — | $ | — | 140,000 | $ | 2,086,750 | ||||||||||
Lawrence J. Baldini | — | $ | — | 9,000 | $ | 134,550 | ||||||||||
Susan D. Rolih | — | $ | — | 9,000 | $ | 134,550 | ||||||||||
Richard L. Eberly3 | 12,500 | $ | 1,875 | 45,500 | $ | 660,150 | ||||||||||
Marco G. Calzavara3 | — | $ | — | 46,000 | $ | 721,000 |
|
|
|
Our 401(k) Savings Plan (“401(k) Plan”) allows all U.S. employees of the Company as soon as administratively possible following their employment to set aside a portion of their compensation each year for their retirement needs, up to the limits set by the Internal Revenue Code. Presently, the Company contributes a matching contribution of 100% of the first 4% of the employee’s contribution (i.e., up to 4% of an employee’s salary), subject to Internal Revenue Code limitations. The Company may also contribute a profit-sharing contribution at its discretion. Employee contributions and employer matching contributions are 100% vested immediately. Participants are entitled to direct the investment of their accounts among various mutual funds selected by the Meridian Bioscience, Inc., Savings and Investment Plan Committee. Participants who terminate employment are entitled to receive the vested portion of their accounts.
POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL
As described on page 21 in the “Compensation Discussion and Analysis” section of this proxy statement, Mr. Kenny and Meridian are parties to the Kenny Employment Agreement which sets forth compensation,non-competition, benefit and severance provisions and provides for a payment equal to twelve months of Mr. Kenny’s then current base salary plus apro-rata portion of the target bonus through the date of termination in the event Mr. Kenny is terminated by Meridian without cause or Mr. Kenny terminates his employment for good reason. If such termination occurs during a change of control period (double trigger), Mr. Kenny is entitled to a severance payment equal to two times his then current base salary plus his target bonus for the severance period.
Had one of the events noted above occurred on September 30, 2018 and Meridian been within a change of control period at that time, Mr. Kenny would also have been entitled to the following under the Kenny Employment Agreement:
Salary | $ | 1,100,000 | ||
Annual Performance Bonus | 385,000 | |||
|
| |||
Total Lump Sum Payment | $ | 1,485,000 | ||
|
|
| $ | 1,380,200 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Annual Performance Bonus
| 1,242,180 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total Lump Sum Payment | $ | 2,622,380 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Our Board of Directors authorized us to enter into change in control severance agreements with our executive officers (other than our CEO, who has a change in control provision in his Employment Agreement). In the case of Mr. Baldasare and Dr. Weltzien, each agreement had an initial term ended December 31, 2016, and each year will automatically renew for an additional one year term, provided however, that if a change in control occurs the term will expire no earlier than 24 calendar months after the calendar month in which such change in control occurs. In the case of Mr. Serafini-Lamanna, his agreement has an initial term ending December 31, 2021, and each year thereafter will automatically renew for a one-year term, provided however, that if a change in control occurs the term will expire no earlier than 24 calendar months after the calendar month in which such change in control occurs. A change in control is generally defined in each agreement as any of the following: (i) a person is or becomes a beneficial owner of more than 50% of our voting securities; (ii) the composition of a majority of our Board changes; (iii) we consummate a merger or similar transaction; or (iv) the sale of all or substantially all of our assets. Each agreement provides, among other things, that if a change in control occurs during the term of the agreement, and the executive’s employment is terminated either by us or by the executive, other than: (a) by us for cause; (b) by reason of death or disability; or (c) by the executive without good reason, such executive will receive a severance payment equal to: (A) a multiple of such executive’s annual base salary; (B) a multiple of executive’s target bonus amounts; and (C) earned but unused vacation time. In addition, each change in control agreement provides that in the event that the severance and other benefits provided for in the agreement or otherwise payable to the executive would be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code, the benefits under the agreement will be either delivered in full or delivered to a lesser extent which would result in no portion of the benefits being subject to such excise tax, whichever is more beneficial to the executive.
Had termination in connection with a change in control occurred on September 30, 2021, the NEOs would have been entitled to the following lump sum payments under the policy:
Bryan T. Baldasare | Lourdes G. Weltzien | Tony Serafini- | ||||||||||
|
| |||||||||||
Salary | $ | 782,800 | $ | 776,696 | $ | 741,600 | ||||||
Annual Performance Bonus | 391,400 | 388,348 | 370,800 | |||||||||
Earned but Unused Vacation | 25,602 | 19,412 | 18,551 | |||||||||
|
| |||||||||||
Total Lump Sum Payment | $ | 1,199,802 | $ | 1,184,456 | $ | 1,130,951 | ||||||
|
|
For fiscal 2021, independent directors of Meridian received the following compensation for service on the Board and the Audit Committee (“AC”), Compensation Committee (“CC”) and Nominating & Corporate Governance Committee (“N&CGC”) (annual amounts presented):
-Base for director service | $ | 40,000 | ||
-Additional for Independent Chairperson | $ | 50,000 | ||
-AC Chair | $ | 20,000 | ||
-AC Member | $ | 10,000 | ||
-CC Chair | $ | 13,000 | ||
-CC Member | $ | 6,000 | ||
-N&CGC Chair | $ | 13,000 | ||
-N&CGC Member | $ | 5,000 |
In addition, each independent director is entitled to receive on an annual basis an equity award grant valued at $100,000. During fiscal 2021, one-third of such equity value was in the form of restricted stock units (valued at the market value of our common stock at the date of award) and two-thirds was in the form of non-qualified options to purchase common shares of the Company at an exercise price equal to the grant date closing sale price as reported on Nasdaq (valued pursuant to the current methodology utilized by the Company for financial reporting purposes, which may be found in Note 12(b) on page 67 of the Company’s Annual Report on Form 10-K filed with the SEC on November 23, 2021).
The following table provides information on compensation related to fiscal 2021 for independent directors who served during fiscal 2021:
Name | Fees Earned or Paid in Cash ($) | Stock ($)1 | Option ($)1 | Non-Equity Incentive Plan Compensation ($) | Change in Pension Value
| All Other ($) | Total ($) | ||||||||||||||||||||||||||||
(a) | (b) | (c) | (d) | (e) | (f) | (g) | (h) | ||||||||||||||||||||||||||||
James M. Anderson | $ | 63,000 | $ | 33,000 | $ | 67,000 | - | - | - | $ | 163,000 | ||||||||||||||||||||||||
Anthony P. Bihl | $ | 59,033 | $ | 33,000 | $ | 67,000 | - | - | - | $ | 159,033 | ||||||||||||||||||||||||
Dwight E. Ellingwood | $ | 48,500 | $ | 33,000 | $ | 67,000 | - | - | - | $ | 148,500 | ||||||||||||||||||||||||
John C. McIlwraith | $ | 47,250 | $ | 33,000 | $ | 67,000 | - | - | - | $ | 147,250 | ||||||||||||||||||||||||
David C. Phillips | $ | 90,000 | $ | 33,000 | $ | 67,000 | - | - | - | $ | 190,000 | ||||||||||||||||||||||||
John M. Rice | $ | 43,750 | $ | 33,000 | $ | 67,000 | - | - | - | $ | 143,750 | ||||||||||||||||||||||||
Catherine A. Sazdanoff | $ | 53,500 | $ | 33,000 | $ | 67,000 | - | - | - | $ | 153,500 | ||||||||||||||||||||||||
Felicia Williams | $ | 60,000 | $ | 33,000 | $ | 67,000 | - | - | - | $ | 160,000 |
1 The amounts shown reflect the grant date fair value of the awards made in fiscal year 2021 in accordance with ASC Topic 718. A discussion of the assumptions used in calculating these values may be found in Note 12(b) on page 67 of the Company’s Annual Report on Form 10-K filed with the SEC on November 23, 2021.
The engagement of the independent consultant by the Compensation Committee to review executive compensation (discussed on page 24) also covered independent director compensation. The following table summarizes the key changes to independent director compensation effective in January 2022 resulting from the counsel of the independent consultant:
Fiscal 2022 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Base for director service | Increase from $40,000 to $50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Compensation Committee | Increase Chair fee from $13,000 to $15,000 and increase member fee from $6,000 to $7,500 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Equity awards | Increase the annual dollar value of the award from $100,000 to $125,000 in January 2022, with a further increase to $150,000 in January 2023; the allocation of the awards between restricted stock units
|